US20040220515A1 - Multilumen catheters and methods for their use - Google Patents

Multilumen catheters and methods for their use Download PDF

Info

Publication number
US20040220515A1
US20040220515A1 US10/771,160 US77116004A US2004220515A1 US 20040220515 A1 US20040220515 A1 US 20040220515A1 US 77116004 A US77116004 A US 77116004A US 2004220515 A1 US2004220515 A1 US 2004220515A1
Authority
US
United States
Prior art keywords
lumen
multilumen
port
catheter
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/771,160
Inventor
Brent Constantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cordis Corp
Original Assignee
Corazon Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corazon Technologies Inc filed Critical Corazon Technologies Inc
Priority to US10/771,160 priority Critical patent/US20040220515A1/en
Assigned to CORAZON TECHNOLOGIES, INC. reassignment CORAZON TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONSTANTZ, BRENT R.
Publication of US20040220515A1 publication Critical patent/US20040220515A1/en
Assigned to CORDIS CORPORATION reassignment CORDIS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CORAZON TECHNOLOGIES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0021Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026Multi-lumen catheters with stationary elements
    • A61M25/0032Multi-lumen catheters with stationary elements characterized by at least one unconventionally shaped lumen, e.g. polygons, ellipsoids, wedges or shapes comprising concave and convex parts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1052Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector

Definitions

  • the field of this invention is atherosclerosis and related vascular conditions, and particularly catheter devices used for treating such conditions.
  • plaques or lesions are a major component of various vascular disease conditions.
  • vascular tissue such as the inner surface of blood vessels, aortic valves, etc.
  • plaques on heart related vascular structures e.g., coronary artery intima, heart valves, etc.
  • plaques or lesions present on the intima of peripheral vessels e.g., arteries, are often implicated in various peripheral vascular disease conditions.
  • U.S. Patents of interest include: U.S. Pat. Nos. 4,329,994; 4,838,881; 5,149,330; 5,167,623; 5,207,648 5,542,937; 6,004,310; and 6,013,068. Also of interest are U.S. Pat. Nos.: 4,445,892; 4,573,966; 4,610,662; 4,636,195; 4,655,746; 4,824,436; 4,911,163; 4,976,733; 5,059,178; 5,090,960; 5,167,628; 5,195,955; 5,222,941; 5,380,284; 5,443,446; and 5,462,529.
  • Multilumen catheters include a proximal end and a distal end separated by an-off-axis or non-coaxial multilumen tube.
  • the subject catheters are further characterized in that they include a multiport manifold at their proximal ends, where at least two of the ports of the multiport manifold comprise a mechanism, e.g., a luer valve, for establishing a sealed fluid communication with the lumen of an external tubular member.
  • kits comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided.
  • systems comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided.
  • the subject multilumen catheters, systems and kits find use in a variety of different applications in which it is desired to flush a vascular site with at least one and preferably two different fluids, where particular applications of interest include the treatment of vascular lesions.
  • FIGS. 1A and 1B each provide a representation of an aspiration catheter according to the subject invention.
  • FIGS. 2A, 2B and 2 C each provide a representation of a total occlusion catheter according to the subject invention.
  • FIGS. 3A, 3B and 3 C each provide a representation of a partial occlusion catheter according to the subject invention.
  • FIG. 4 provides a representation of a total occlusion catheter system according to the subject invention.
  • FIG. 5 provides a representation of a partial occlusion catheter system according to the subject invention.
  • FIG. 6 shows the distal end of a total occlusion catheter system flushing a target vascular site in a method according to the subject invention.
  • Multilumen catheters are provided.
  • the subject multilumen catheters include a proximal end and a distal end separated by an off-axis or non-coaxial multilumen tube.
  • the subject catheters are further characterized in that they include a multiport manifold at their proximal ends, where at least two of the ports of the multiport manifold comprise a mechanism, e.g., a luer valve, for establishing a sealed fluid communication with the lumen of an external tubular member.
  • kits comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided.
  • systems comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided.
  • the subject multilumen catheters, systems and kits find use in a variety of different applications in which it is desired to flush a vascular site with at least one and preferably two different fluids, where particular applications of interest include the treatment of vascular lesions.
  • the present invention provides multilumen catheters.
  • the subject invention includes three different multilumen catheters, which can be used together as a system to simultaneously flush a vascular site with two distinct fluids.
  • Common features of each catheter of the subject invention are that they include a proximal end and a distal end separated by an elongated non-coaxial multilumen tube.
  • non-coaxial multilumen tube it is meant a tube that includes at least two lumens which are non-coaxial, i.e., they do not share a common axis.
  • the number of lumens in the multilumen tube may vary, but generally is 2 to 5, and is often 2 to 4, where in certain embodiments the number is 2 or 3.
  • elongated it is meant that the distance between the proximal and distal ends is sufficient for the catheter to be inserted or introduced into the vascular system of a patient at a site remote from the vascular lesion that is to be treated through action of the distal end of the catheter, as is known in the art.
  • Catheters intended for intravascular introduction will typically have a length in the range from 50 cm to 200 cm and an outer diameter in the range from 1 French (0.33 mm; Fr.) to 12 Fr., usually from 3 Fr. to 9 Fr.
  • the length is typically in the range from 125 to 200 cm, the diameter is preferably below 8 Fr., more preferably below 7 Fr., and most preferably in the range from 2 Fr. to 7 Fr.
  • the elongated tubular element has a length of from about 80 to 200 cm, usually from about 90 to 180 cm and more usually from about 90 to 140 cm.
  • All of the subject multilumen catheters are further characterized in that they include a multiport manifold at their proximal ends.
  • multiport manifold is meant a manifold that includes two or more ports (in addition to the attachment structure of the mannifold to the proximal end of the elongated tube of the catheter), where the number of ports in the manifold may range from 2 to 4, but is generally 2 or 3, depending on the particular multilumen catheter.
  • at least two of the ports of the multiport manifold preferably have luer valves or analogous means for establishing a sealed fluid communication with the lumen of an external tubular element or analogous fluid conveying means.
  • a luer valve is present in these ports, where the valve may be a male or female luer valve.
  • Luer valves are disclosed in U.S. Pat. Nos. 6,063,062; 6,039,302; 5,954,313; 5,947,954; 5,788,215; 5,775,671; 5,738,144; 5,549,651; 5,535,785; 5,474,544; 5,441,487; 5,372,143; 5,284,475; the disclosures of which are herein incorporated by reference.
  • the multiport manifold is a two port manifold, each of the two ports in the manifold will typically have a luer valve.
  • the multiport manifold is a three port manifold, only two of the three ports may have luer valves or all three ports may have luer valves.
  • the elongated multilumen tube is typically a polymeric extruded element, which is made up of one or more biocompatible polymers that have been extruded to produce the non-coaxial multilumen tube.
  • Biocompatible polymers of interest include, but are not limited to: polyimide, polyamide, PBAXTM, polyethylene, polyisoprene, nylon and the like.
  • each of the disparate multilumen catheters share the above common features, there are differences between the different specific multilumen catheter designs of the subject invention. As such, each specific type of multilumen catheter of the subject invention, e.g., aspiration, total and partial multilumen catheters, will now be described separately in greater detail.
  • the first multilumen catheter of the subject invention is identified herein as the aspiration catheter, as it includes the lumen employed for aspiration when the catheter is used in a system for flushing a vascular site with fluid.
  • the aspiration catheter is characterized by having a proximal end and a distal end separated by a non-coaxial two lumen tube, where a three port manifold is present at the proximal end.
  • a three port manifold two of the ports, and more specifically the side or offset ports, have luer valves, while the central port has a valve capable of opening and closing around a tubular element, e.g., a catheter, dilator, guidewire, etc., to produce a sealed relationship with the tubular element.
  • this element is a Touhy-Borst valve or analogous structure, where Touhy-Borst valves are described in U.S. Pat. Nos. 5,795,307 and 5,320,613; the disclosures of which are herein incorporated by reference.
  • FIGS. 1A and B provide a depiction of a representative aspiration catheter according to the subject invention.
  • aspiration catheter 10 has proximal end 14 and distal end 12 separated by elongated non-coaxial two lumen tube 16 .
  • the length of elongated tube 16 should be long enough to provide for access of the distal end to the target vascular site upon introduction into the host, subject or patient at a remote site, and typically ranges from about 80 to 200 cm, usually from about 90 to 180 cm and more usually from about 90 to 140 cm.
  • the outer diameter of the elongate tubular member 16 may vary depending on the target vascular site for which it is designed to be used.
  • the outer diameter of the aspiration catheter is selected so as to provide for access of the distal end of the catheter to the vascular site via the vascular system from the remote point of entry, where the outer diameter typically ranges from about 1.0 to 4.0 mm (3 to 12 Fr), usually from about 1.5 to 3.0 mm (4.5 to 9.0 Fr) and more usually from about 1.7 to 2.7 mm (5 to 8 Fr).
  • the length is typically in the range from 125 to 200 cm, the diameter is preferably below 8 Fr., more preferably below 7 Fr., and most preferably in the range from 2 Fr. to 7 Fr.
  • the aspiration catheter is further characterized in that one of the two lumens, generally the larger of the two lumens, opens at the distal end, thereby providing a fluid entry site for fluid from the target vascular site to flow into the lumen.
  • this larger lumen is designated 17 .
  • the inner diameter of this lumen at the open distal end and along the entire length of the tube 16 is sufficient to house either a partial or total occlusion multilumen catheter, as described in greater detail below, and remove fluid from the vascular site at the desired rate, e.g., a rate that provides for substantially isometric or isobaric pressure in the vascular site during treatment, through the resultant annular space.
  • This larger lumen 17 is also known as the aspiration lumen.
  • the inner diameter of the aspiration lumen 17 is sufficient to provide for adequate flow into the lumen of the catheter, and sometimes ranges from about 0.20 to 2.0, usually from about 0.25 to 1.75 and more usually from about 0.35 to 1.5 mm.
  • a vessel occlusion means 13 is also present at the distal end of the aspiration catheter 10 , where the vessel occlusion means is usually an inflatable balloon.
  • the balloon 13 is one that is inflatable to a volume sufficient to substantially occlude the vessel in which the aspiration catheter is positioned, e.g., by pressing against the intimal surface of the vessel in which the aspiration catheter is positioned.
  • the inflated balloon diameter generally ranges from about 2 to 30 mm, usually from about 5 to 20 mm.
  • the inflated balloon length typically ranges from about 10 to 30 mm, usually from about 15 to 20 mm.
  • the balloon is in fluid or gaseous communication with an inflation lumen 19 which is the other lumen of the two lumen tube and runs the length of the aspiration catheter from the balloon to the proximal end, but does not open up at the distal end of the catheter.
  • the inflation lumen typically has an inner diameter that ranges from about 0.1 to 0.5 mm, usually from about 0.2 to 0.4 mm.
  • the aspiration catheter further includes a separate guidewire lumen (not shown). However, in many embodiments, a separate guidewire lumen is not present.
  • Three port manifold 18 includes side or offset ports 11 a and 11 c , as well as central port 11 b .
  • One of the offset ports, e.g., 11 a is in fluid communication with the smaller lumen 19 and is attached to a balloon inflation means, e.g., a syringe filled with gas or fluid, during use.
  • the other offset port, e.g., 11 c is in fluid communication the larger aspiration lumen 17 and is attached to a source of negative pressure, e.g., a vacuum, during use.
  • Offset ports 11 a and 11 c are further characterized in having or being in communication with luer valves 15 a and 15 c , respectively.
  • luer valves 15 a and 15 c are female luer valves.
  • Central port 11 b is in fluid communication with the aspiration lumen 17 and provides the point of access for the total and partial occlusion catheters, described in greater detail below.
  • two of the ports of the manifold specifically the central port and one of the offset ports, are in fluid communication with the aspiration lumen 17 .
  • Central port 11 b is characterized by the presence of Touhy-Borst valve 15 b or an analogous structure. Touhy-Borst valves suitable for use in medical devices, e.g., catheters, are described in U.S. Pat. No. 5,320,613 and 5,795,307.
  • a strain relief 18 a Also present on the catheter shown in FIG. 1A is a strain relief 18 a .
  • the strain relief protects the proximal end of tube 16 from damage and gives strength to the transition between the tube and manifold 18 .
  • the strain relieve locally increases the stiffness of tube 16 to provide a moderated step-wise increase in stiffness from the relatively more flexible tube to the stiffer manifold member.
  • the length of the strain relieve may varies from 5 to 40 mm, but is usually 20 to 30 mm in length.
  • Suitable materials for strain relief 18 a include fluorinated ethylene-propylene or a similar medical grade polymer.
  • FIG. 1A includes three-way stop cocks attached to each of the offset ports. These provide for further control of fluid flow into the lumens of the device and/or the introduction of two separate fluids into the same lumen of the device, e.g., an imaging solution into the aspiration lumen and aspiration of fluid through the aspiration lumen, depending on the state of the three way stop-cock.
  • each of the ports of the three port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. vacuum source, balloon inflation means, etc.
  • the offset ports may have a yellow band, one may have a green band and one may have a red band, thereby uniquely identifying the ports of the three port manifold.
  • multilumen catheters that are designed to be inserted inside the aspiration lumen and used to flush a vascular site that is characterized by the presence of a total vascular occlusion, e.g., as shown in FIG. 6 described in greater detail below.
  • These catheters are identified herein as total occlusion catheters.
  • the total occlusion catheters are characterized in that the multilumen tube separating the proximal and distal ends is a two lumen tube.
  • the multiport manifold is preferably a two port manifold, where both of the ports have luer valves.
  • the multilumen total occlusion aspiration catheter further includes a guidewire lumen.
  • FIGS. 2A and B and C each provide a representation of a total occlusion catheter according to the subject invention.
  • total occlusion catheter 20 includes proximal end 24 and distal end 22 separated by elongated tubular member 26 .
  • Elongated tubular member 26 is sufficiently long to provide for access of the distal end to the target vascular site upon introduction into the host vascular system via a remote entry site of the vascular system.
  • the length of elongate member 26 ranges from about 90 to 210 cm, usually from about 100 to 190 cm and more usually from about 110 to 150 cm.
  • the outer diameter of the tubular member 26 is such that it may be slidably positioned inside the aspiration lumen of the aspiration catheter, as described above.
  • the outer diameter of element 26 ranges from about 0.5 to 2.0 (1.5 to 6.0 Fr), usually from about 0.8 to 1.6 mm (2.5 to 5 Fr).
  • Tubular member 26 is a two lumen tubular member, where the lumens of the catheter are non-coaxial. Each of the lumens, 25 and 27 , open at the distal end of catheter 20 . One of the lumens is designed to carry a first fluid and the other is designed to carry a second fluid. In many embodiments, the first fluid is a dissolution fluid and the second fluid is a dissolution fluid attenuating fluid, as described in greater detail below.
  • FIG. 2B is a cross section of tubular member 26 taken at line A-A shown in FIG. 2A.
  • lumen 25 has a substantially circular configuration while lumen 27 has a crescent configuration so as to share a common wall or border with a substantial portion of lumen 25 , where by “substantial portion” is meant at least 25%, usually at least 35% and more usually at least 50% of the circumference of lumen 25 , where in certain embodiments this portion may be much higher, e.g., 60%, 75% etc.
  • Lumen 25 is typically employed for conveying the dissolution fluid while lumen 27 is typically employed for conveying the dissolution fluid attenuating fluid during use.
  • FIG. 2C the cross sectional view show a three lumen total occlusion catheter, where lumen 25 a is employed for dissolution solution, lumen 27 is employed for dissolution fluid attenuating fluid delivery and lumen 29 is the guidewire lumen.
  • the inner diameter of lumen 25 typically ranges from about 0.2 to 1.0 mm, usually from about 0.2 to 0.7 mm and more usually from about 0.3 to 0.4 mm, so as to provide for a cross-sectional area of about 0.03 to 0.8 mm 2 , usually from about 0.03 to 0.4 mm 2 and more usually from about 0.07 to 0.2 mm 2 .
  • the cross-sectional area of lumen 27 typically ranges from about 0.03 to 0.8 mm 2 , usually from about 0.03 to 0.4 mm 2 and more usually from about 0.07 to 0.2 mm 2 . While the configuration of FIG. 2B shows a circular and crescent shaped lumen, other configurations are also possible, e.g., two circular lumens, to semicircular lumens, etc.
  • Two port manifold 28 includes side or offset port 21 a and central port 21 b .
  • Port 21 a includes female luer valve 23 a while port 23 b includes high pressure female luer valve 23 b .
  • side or offset port 21 a is typically in fluid. communication with a source of dissolution fluid attenuating fluid, e.g., buffer, while central port 23 b is typically in fluid communication with a source of dissolution fluid, e.g., acid solution.
  • a strain relief 28 a Also present on the catheter shown in FIG. 2A is a strain relief 28 a . It functions as described in connection with strain relief 18 a .
  • a strain relief 28 a also present is three-way stop cock attached to the central port which provides for further control of fluid flow into the central lumens of the device, the introduction of two separate fluids into the same lumen of the device and/or the introduction of separate fluids for intermittent flushing, e.g. with heparinized saline, typically used to keep lumens clear and prevent clotting.
  • each of the ports of the two port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. dissolution fluid reservoir, dissolution fluid attenuating fluid reservoir, etc.
  • one of the offset ports may have a yellow band and one may have a red band, thereby uniquely identifying the ports of the manifold.
  • multilumen catheters that are designed to be inserted inside the aspiration lumen and used to flush a vascular site that is characterized by the presence of a partial vascular occlusion.
  • catheters are identified herein as partial occlusion catheters.
  • the partial occlusion catheters are characterized in that the multilumen tube separating the proximal and distal ends is a three lumen tube.
  • the multiport manifold is a three port manifold, where each of the ports has a luer valve or analogous structure.
  • the partial occlusion catheter also includes a balloon or analogous vessel occlusion means at its distal end and multiple ports proximal to the balloon, where a portion of these infusion ports are in fluid communication with one of the lumens and the remainder are in fluid communication with another of the lumens.
  • the partial occlusion catheters of the subject invention further include a guidewire lumen, bring the total number of lumens in the partial occlusion catheter to four.
  • FIGS. 3A, B and C provide a representation of a partial occlusion catheter according to the subject invention.
  • partial occlusion catheter 30 includes distal end 32 and proximal end 34 separated by three lumen tube 36 .
  • the length of the tubular member 36 generally ranges from about 90 to 250 cm, usually from about 100 to 230 cm and more usually from about 110 to 190 cm.
  • the outer diameter of the tubular member 36 is such that the partial occlusion catheter 30 may be slidably positioned in the aspiration lumen of the aspiration catheter.
  • the outer diameter of tubular member 36 typically ranges from about 0.5 to 2.0, usually from about 0.8 to 1.6 mm.
  • balloon 31 Located at the distal end of catheter 30 is balloon 31 or analogous occlusion means.
  • the balloon is generally one that is inflatable to a diameter ranging from about 2 to 15 mm, usually about 5 to 10 mm, and typically has a length of from about 10 to 30 mm, usually from about 15 to 20 mm.
  • Proximal to the balloon 31 are a series of ports 43 , 45 and 47 which provide for fluid transfer between the outside of tube 36 and the lumens located inside the device.
  • ports 43 and 45 are in fluid communication with a first lumen inside the tube 36 that is carrying dissolution fluid attenuating fluid while port 47 is in fluid communication with the lumen of the device carrying the dissolution fluid.
  • the diameter of the infusion ports may vary, but typically ranges from about 0.2 to 1.2, usually from about 0.4 to 1.0 and more usually from about 0.5 to 0.8 mm.
  • FIG. 3B shows the cross section of tube 36 taken along line A-A as shown in FIG. 3A.
  • lumen 37 has a substantially circular cross section, while lumens 39 and 41 together make up a crescent shape that shares a border with lumen 37 that extends for a substantial portion of the perimeter of lumen 37 .
  • the crescent shape made through combination of lumens 39 and 41 is divided to provide for distinct lumens 39 and 41 .
  • the diameter of lumen 37 typically ranges from about 0.02 to 1.0 mm, usually from about 0.2 to 0.7 mm and more usually from about 0.3 to 0.4 mm to provide a cross-sectional area ranging from about 0.03 to 0.8 mm 2 , usually from about 0.03 to 0.4 mm 2 .
  • the cross sectional area of lumen 39 typically ranges from about 0.03 to 0.8 mm 2 , usually from about 0.03 to 0.4 mm 2 while the cross-sectional area of lumen 41 typically ranges from about 0.05 to about 0.3, usually from about 0.1 to about 0.2.
  • lumen 37 conveys dissolution fluid attenuating fluid, e.g., buffer, and/or provides for guidewire use
  • lumen 39 conveys dissolution fluid, e.g., acid
  • lumen 41 conveys inflation medium, e.g., gas or fluid, to the balloon. While one type of configuration of the various lumens is shown, other non-coaxial configurations are also possible, e.g., three separate circles, a circle and two distinct crescent shapes, etc., where all of these potential configurations are within the scope of the invention.
  • FIG. 3C provides a cross-section view of an embodiment that includes a guidewire lumen. As such, in FIG. 3C one can see the balloon lumen 41 , the dissolution fluid and dissolution fluid conveyance lumens, 39 and 37 a , as well as the guidewire lumen 42 .
  • Three port manifold 38 Located at the proximal end 34 of catheter 30 is three port manifold 38 .
  • Three port manifold 38 includes two offset or side ports 33 a and 33 c , which flank central port 33 b .
  • Each of the ports includes a female luer valve, 35 a , 35 b and 35 c .
  • the central port 33 b is typically in fluid communication with a dissolution fluid attenuating fluid source during use.
  • Offset port 33 a is typically in fluid communication with a source of dissolution fluid.
  • Offset port 33 c is typically in fluid communication with a balloon inflation means, e.g., a syringe filled with a gas or liquid.
  • strain relief 38 a Also present on the catheter shown in FIG. 3A is a strain relief 38 a . It functions in the manner of strain relief 18 a and 28 a.
  • FIG. 3A also present are three-way stop cocks attached to each of the offset ports, which elements provide for further control of fluid flow into the lumens of the device, the introduction of two separate fluids into the same lumen of the device and/or the introduction of separate fluids for intermittent flushing, e.g. with heparinized saline, typically used to keep lumens clear and prevent clotting, depending on the state of the three way stop-cock.
  • each of the ports of the three port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. vacuum dissolution fluid, dissolution fluid attenuating fluid, balloon inflation means, etc.
  • flushing a vascular site is meant introducing fluid into and removing fluid from a vascular site at substantially the same time such that the vascular site remains substantially stable in terms of pressure, e.g., is isobaric, where the pressure changes that occur in the vascular site do not exceed in magnitude a value of about 50 mm Hg and usually do not exceed about 30 mm Hg. Accordingly, maximum pressure will typically remain below about 400 mm Hg, preferably about 100 mm Hg.
  • the subject systems are characterized by having an aspiration catheter and one of the total or partial occlusion catheters of the subject invention in a nested configuration, such that the total or partial occlusion catheter is slidably positioned inside the aspiration lumen of the aspiration catheter.
  • FIG. 4 provides a representation of a system designed for use with a total occlusion which is made up of a total occlusion catheter 20 inserted into the aspiration lumen of an aspiration catheter.
  • FIG. 5 provides a representation of a system designed for use in the treatment of a partial occlusion, where the system is made up of a partial occlusion catheter inserted into the aspiration lumen of an aspiration catheter.
  • the central manifold port of the aspiration catheter may have a Touhy-Borst valve, a fluid seal can be produced at the interface between the aspiration manifold central port and the outer surface of the partial or total occlusion catheter when inserted into the aspiration lumen of the aspiration catheter.
  • one of the offset ports of the aspiration manifold is often in fluid communication with a syringe balloon inflation means and the other offset port of the aspiration manifold is in fluid communication with a vacuum source to provide the force for removing fluid from the vascular site via the aspiration lumen.
  • the central port of the total occlusion manifold is in fluid communication with a source of dissolution fluid, e.g., an ENDoFLATOR®, etc.
  • the offset port of the total occlusion manifold is in fluid communication with a source of dissolution fluid attenuating fluid, e.g., an ENDoFLATOR®, etc.
  • one of the offset ports of the aspiration manifold is often in fluid communication with a balloon inflation mechanism, e.g., a fluid or gas filled syringe, and the other offset port of the aspiration manifold is in fluid communication with a vacuum source.
  • the central port of the partial occlusion manifold is in fluid communication with a source of dissolution fluid attenuating fluid, e.g., an ENDoFLATOR® filled with dissolution fluid attenuating fluid, while one of the offset ports is in fluid communication with a source of dissolution fluid, e.g.
  • each of the catheters are filled with the respective solutions for which sources are provided.
  • balloons provided will be at least partially filled, together with adjacent feed lumen in use.
  • the aspiration lumen may also be subject to at least partial vacuum.
  • the subject systems find use in applications where it is desired to simultaneously flush a vascular target site with two different fluids.
  • flush it is meant that the fluid is introduced into the vascular site and removed from the vascular site is accomplished in manner such that the vascular site remains at substantially constant pressure.
  • the pressure throughout the treatment site is predicted to be, on average, lower than the backbleed pressure, i.e., the blood pressure on the proximal side of the aspiration catheter balloon.
  • the subject systems can, in principle, be employed to flush a vascular site with any two fluids, they are particularly suited for use in applications where chemical tissue ablation at a target vascular site is desired.
  • the subject systems find particular use in the treatment of vascular lesions or obstructions, where the target lesions or obstructions may be organic, inorganic or composite structures of both organic and inorganic components.
  • the systems are used to flush the target vascular site, and therefore the lesion or obstruction located therein, with a dissolution fluid and a dissolution fluid attenuating fluid.
  • the first step is generally to provide for an entry site for the catheter into the vascular system of the host. Entry is typically provided by placement of an introducer sheath at a convenient location, e.g. leg etc., as is known in the art. A guidewire is then inserted through the entry sheath and its distal end is placed at the target vascular site. The aspiration catheter with a dilator present in the central lumen is then moved over the guidewire, where the guidewire generally passes through the central lumen, so that the distal end of the aspiration catheter reaches the target vascular site.
  • the dilator is removed and replaced with either the partial or total occlusion catheter inserted through the Touhy-Borst valve of the aspiration manifold central port and into the aspiration lumen.
  • This catheter insert is then moved through the lumen, optionally over the guidewire if still present, until the distal end of the insert is beyond the distal end of the aspiration catheter.
  • the distal end of the insert will extend some distance beyond the distal end of the aspiration catheter, where this distance typically does not exceed about 20 cm and usually does not exceed about 5 mm.
  • the dissolution fluid and dissolution fluid attenuating fluid are introduced into the vascular site via the appropriate lumens inside the catheter insert and fluid is removed from the vascular site via the aspiration lumen of the aspiration catheter, and specifically through the annular space present in the system bordered by the inner wall of the aspiration lumen and the outer wall of the catheter insert.
  • the nature of the dissolution fluid and the dissolution fluid attenuating fluid necessarily depends on the nature of the target lesion to be treated. For example, for organic matter comprising lesions, organic matter dissolution fluids (and their companion attenuating fluids) are of interest, such as those described in U.S. patent application Ser. No.
  • the dissolution fluid employed in the subject methods is an inorganic matter dissolution solution.
  • the inorganic matter dissolution fluid is an acidic dissolution fluid.
  • the acidic treatment solutions that find use in the subject methods generally have a pH of less than about 6.5, where the pH is usually less than about 4.0 and more usually less than about 3.0. In many preferred embodiments, the pH ranges from 0 to 2, and usually 0 to 1.
  • the acidic treatment solution can include a number of different types of acids, where the acids may or may not include a hydrocarbon moiety, i.e., a hydrogen bonded directly to a carbon atom.
  • Suitable acids that lack a hydrocarbon moiety include halogen acids, oxy acids and mixtures thereof, where specific acids of interest of this type include, but are not limited to, hydrochloric, nitric, sulfuric, phosphoric, hydroboric, hydrobromic, carbonic and hydroiotic acids.
  • the acid can be a concentrated acid, or can be diluted. Upon dilution, the concentration of an inorganic acid will generally be from about 10 N to about 0.01 N, preferably between 5 N to 0.1 N.
  • acids that include a hydrocarbon moiety where such acids include, but are not limited to, any organic acid of one to six (C 1 to C 6 ) carbons in length.
  • Organic acids of this type include, but are not limited to, formic, acetic, propionic, maleic, butanoic, valeric, hexanoic, phenolic, cyclopentanecarboxylic, benzoic, and the like.
  • the acid can be in concentrated form, or can be diluted.
  • the acidic treatment solution can be composed of either a monobasic or a polybasic acid. Acids are “monobasic” when they have only one replaceable hydrogen atom and yield only one series of salts (e.g., HCl). Acids are “polybasic” when they contain two or more hydrogen atoms which may be neutralized by alkalies and replaced by organic radicals.
  • the acid solution is hypertonic, by which is meant that the osmolarity of the solution is greater than that of whole blood, i.e. the osomolarity is greater than 300 mosmol.
  • the solution may be rendered hypertonic by including any convenient component or components in the solution that provide for the desired elevated osmolarity.
  • any convenient agent that is capable of increasing the osmolarity of the solution may be employed, where suitable agents include salts, sugars, and the like.
  • the agent that is employed to render the solution hypertonic is one or more, usually no more than three, and more usually no more than two, different salts.
  • the salt concentration in these embodiments of the solution is at least about 100 mosmol, usually at least about 200 mosmol and more usually at least about 300 mosmol, where the concentration may be as high as 3000 mosmol or higher, depending on the particular salt being employed to render the solution hypertonic, where the solution may be saturated with respect to the salt in certain embodiments.
  • Salts that may be present in the subject solutions include: NaCl, MgCl 2 , Ringers, etc. where NaCl is preferred in many embodiments.
  • the concentration of HCl in the solution ranges from about 0.001 to 1.0 N, usually from about 0.01 to 1.0 N and more usually from about 0.1 to 1.0 N.
  • the hydrogen chloride solution will further include one or more salts which make the solution hypertonic, as described above.
  • the salt is NaCl, where the concentration of NaCl in the solution is at least 0.05 M, usually at least 0.10 M, and more usually at least 0.15 M, where the concentration may be as high as 0.25 M or higher.
  • the solution will be saturated with NaCl.
  • aqueous hydrogen chloride solutions that consist of water, hydrogen chloride and NaCl.
  • concentration of hydrogen chloride in these solutions of particular interest ranges from about 0.01 to 1.0 N, usually from about 0.05 to 0.5 N and more usually from about 0.075 to 0.25 N.
  • concentration of NaCl in these solutions of particular interest ranges from about 0.05 to 0.25 M, usually from about 0.05 to 0.10 M.
  • one or more of the delivery fluids is present at a temperature that is less than room temperature.
  • the one or more treatment solutions, as described above is present at a temperature ranging from about 0 to about 20° C., sometimes from about 0 to 15° C., e.g., from about 0 to 10° C.
  • Such embodiments include applications where it is desired to limit restinosis by employing reduced temperature, e.g., cold, solutions.
  • FIG. 6 provides a representation of the distal end of a total occlusion catheter system flushing a target vascular site with an acidic dissolution fluid and a buffer dissolution fluid attenuating fluid.
  • the target vascular site 61 is shown with total vascular occlusion 62 .
  • the distal end of total occlusion catheter system 60 is shown with aspiration catheter 10 and total occlusion catheter 20 extending beyond the end of aspiration catheter 10 .
  • Acidic dissolution fluid 63 exits lumen 25 while buffer dissolution fluid attenuating fluid 64 exits lumen 27 .
  • Fluid comprising acid, buffer and dissolved plaque, i.e., 65 is withdrawn from the vascular site by the annular opening of the aspiration lumen of the aspiration catheter.
  • the target vascular site is flushed with the dissolution and dissolution fluid attenuating fluids for a period of time sufficient to result in the desired amount of treatment, e.g., target lesion size reduction, enhancement or establishment of fluid flow through the target site, etc.
  • the system is removed from the host. More specific detail regarding the methods in which the subject systems find use can be found in U.S. Pat. No. 09/528,576; the disclosure of which is herein incorporated by reference; and publication no. WO 00/03651 the disclosure of the priority document of which is herein incorporated by reference.
  • external energy is applied to the target aortic valve to promote mechanical break-up of the calcified deposits into particles or debris that can be easily removed from the vascular site.
  • Any means of applying external energy to the aortic valve may be employed.
  • jets or other such means the device which are capable of providing varying external forces to the target deposits cause the target deposit to break up or disrupt may be employed.
  • sonic energy e.g., ultrasound.
  • Another means that may be employed to apply external energy to the lesion during the dissolution process is to use a mechanical means of applying external energy.
  • Mechanical means of interest include moving structures, e.g. rotating wires, guidewires, which physically contact the target lesion and thereby apply physical external energy to the target lesion.
  • kits for use in flushing a vascular site with two fluids at least include the components of a partial occlusion or total occlusion catheter system according to the subject invention.
  • the kits include an aspiration catheter and at least one of a partial occlusion catheter and a total occlusion catheter.
  • the kits include both a partial occlusion catheter and a total occlusion catheter.
  • the subject kits may also include a dissolution fluid and/or dissolution fluid attenuating fluid, or components/precursors thereof, where representative dissolution fluids and dissolution fluid attenuating fluids are disclosed above.
  • the dissolution fluids and dissolution fluid attenuating fluids or component(s) thereof are present in the kit in a suitable container, e.g., a bottle, pouch, fluid filled Endeflator, etc. which is capable of serving as a storage vessel for the this component of the kit and, preferably, capable of preserving the sterility of this component of the kit, as this component of the kit is preferably sterile, e.g., medical grade.
  • a suitable container e.g., a bottle, pouch, fluid filled Endeflator, etc. which is capable of serving as a storage vessel for the this component of the kit and, preferably, capable of preserving the sterility of this component of the kit, as this component of the kit is preferably sterile, e.g., medical grade.
  • kits of the subject invention may also include a number of different optional components, which components may find use in methods in which the subject kit components are employed.
  • One optional component that may be present in the subject kits is a guidewire. Any convenient type of guidewire may be present, where a number of different guidewires are known to those of skill in the art. Guidewires of interest include those described in U.S. Pat. Nos.
  • kits of the subject invention include various fluids and solutions in addition to the dissolution fluid and dissolution fluid attenuating fluid described above. Additional fluids that may be present include: organic matter dissolution fluids, wash or rinsing fluids, imaging agent fluid mediums that include an imaging agent, such as a non-ionic imaging agents, e.g., CONRAYTM, OXILANTM, fluids containing one or more pharmacological agents, e.g., agents that promote healing, reduce inflammation, and the like; etc.
  • an imaging agent such as a non-ionic imaging agents, e.g., CONRAYTM, OXILANTM
  • pharmacological agents e.g., agents that promote healing, reduce inflammation, and the like
  • kits include one or more additional components and accessories for use with the fluid delivery means present in the kit, including tubing for connecting the various catheter components with fluid reservoirs, syringes, pumps, etc., connectors, stop-cocks, dilators, insertion sheaths, vacuum regulators, negative pressure or vacuum generators/sources, luer valve adapters, etc.
  • the subject kits typically further include instructions for using the components of the kit to flush a vascular site with two different fluids, e.g., to flush a vascular site with a dissolution fluid and a dissolution fluid attenuating fluid.
  • the instructions for practicing the subject methods are generally recorded on a suitable recording medium.
  • the instructions may be printed on a substrate, such as paper or plastic, etc.
  • the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc.
  • the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g.
  • the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
  • An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

Abstract

Multilumen catheters are provided. The subject multilumen catheters include a proximal end and a distal end separated by a non-coaxial multilumen tube. The subject catheters are further characterized in that they include a multiport manifold at their proximal ends, where at least two of the ports of the multiport manifold may comprise luer valves. Also provided are systems for use in flushing a vascular site with fluid, usually at least two different fluids, where the subject systems are made up of two multilumen catheters according to the subject invention, where one of the catheters is inserted inside of the other. In addition, kits comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided. The subject multilumen catheters, systems and kits find use in a variety of different applications in which it is desired to flush a vascular site with at least one and preferably two different fluids, where particular applications of interest include the treatment of vascular lesions.

Description

    FIELD OF THE INVENTION
  • The field of this invention is atherosclerosis and related vascular conditions, and particularly catheter devices used for treating such conditions. [0001]
  • BACKGROUND OF THE INVENTION
  • The formation of plaques or lesions (atherosclerotic plaques or lesions), on vascular tissue, such as the inner surface of blood vessels, aortic valves, etc., is a major component of various vascular disease conditions. For example, plaques on heart related vascular structures, e.g., coronary artery intima, heart valves, etc., are often implicated in various heart disease conditions. Likewise, plaques or lesions present on the intima of peripheral vessels, e.g., arteries, are often implicated in various peripheral vascular disease conditions. [0002]
  • A variety of different protocols have been developed for treating diseases associated with the presence of vascular lesions or plaques. Such treatment methodologies generally involve mechanical removal or reduction of the lesion, and include: bypass surgery, balloon angioplasty, mechanical debridement, atherectomy, valve replacement, and the like. Despite the plethora of different treatment strategies that have been developed for the treatment of such vascular disease conditions, there are disadvantages associated with each technique, such as tissue damage, invasiveness, etc. For example, restenosis is a common complication that results in arteries in which lesions have been mechanically removed. [0003]
  • As such, there is continued interest in the development of new treatment protocols for the removal of vascular lesions from vascular tissue, as well as catheter devices that are used in such protocols. [0004]
  • Literature [0005]
  • U.S. Patents of interest include: U.S. Pat. Nos. 4,329,994; 4,838,881; 5,149,330; 5,167,623; 5,207,648 5,542,937; 6,004,310; and 6,013,068. Also of interest are U.S. Pat. Nos.: 4,445,892; 4,573,966; 4,610,662; 4,636,195; 4,655,746; 4,824,436; 4,911,163; 4,976,733; 5,059,178; 5,090,960; 5,167,628; 5,195,955; 5,222,941; 5,380,284; 5,443,446; and 5,462,529. See also: WO 00/03651; WO 01/13985; WO 01/15767; WO 01/39783; WO 01/70320; and WO 02/15958; the disclosures of the priority documents of which are herein incorporated by reference. [0006]
  • SUMMARY OF THE INVENTION
  • Multilumen catheters are provided. The subject multilumen catheters include a proximal end and a distal end separated by an-off-axis or non-coaxial multilumen tube. The subject catheters are further characterized in that they include a multiport manifold at their proximal ends, where at least two of the ports of the multiport manifold comprise a mechanism, e.g., a luer valve, for establishing a sealed fluid communication with the lumen of an external tubular member. Also provided are systems for use in flushing a vascular site with fluid, usually at least two different fluids, where the subject systems are made up of two multilumen catheters according to the subject invention, where one of the catheters is inserted inside of the other catheter in a nesting configuration. Catheters so-configured and filled with such fluids are included in the invention. In addition, kits comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided. In addition, systems comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided. The subject multilumen catheters, systems and kits find use in a variety of different applications in which it is desired to flush a vascular site with at least one and preferably two different fluids, where particular applications of interest include the treatment of vascular lesions. [0007]
  • BRIEF DESCRIPTION OF THE FIGURES
  • Each of the following figures provide examples diagrammatically illustrating aspects of the present invention. [0008]
  • FIGS. 1A and 1B each provide a representation of an aspiration catheter according to the subject invention. [0009]
  • FIGS. 2A, 2B and [0010] 2C each provide a representation of a total occlusion catheter according to the subject invention.
  • FIGS. 3A, 3B and [0011] 3C each provide a representation of a partial occlusion catheter according to the subject invention.
  • FIG. 4 provides a representation of a total occlusion catheter system according to the subject invention. [0012]
  • FIG. 5 provides a representation of a partial occlusion catheter system according to the subject invention. [0013]
  • FIG. 6 shows the distal end of a total occlusion catheter system flushing a target vascular site in a method according to the subject invention.[0014]
  • DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • Multilumen catheters are provided. The subject multilumen catheters include a proximal end and a distal end separated by an off-axis or non-coaxial multilumen tube. The subject catheters are further characterized in that they include a multiport manifold at their proximal ends, where at least two of the ports of the multiport manifold comprise a mechanism, e.g., a luer valve, for establishing a sealed fluid communication with the lumen of an external tubular member. Also provided are systems for use in flushing a vascular site with fluid, usually at least two different fluids, where the subject systems are made up of two multilumen catheters according to the subject invention, where one of the catheters is inserted inside of the other catheter in a nesting configuration. Catheters so-configured and filled with such fluids are included in the invention. In addition, kits comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided. In addition, systems comprising various components of the subject systems, e.g., at least two different multilumen catheters, are provided. The subject multilumen catheters, systems and kits find use in a variety of different applications in which it is desired to flush a vascular site with at least one and preferably two different fluids, where particular applications of interest include the treatment of vascular lesions. [0015]
  • Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims. [0016]
  • It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. [0017]
  • Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and such embodiments are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. [0018]
  • All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing components that are described in the publications that might be used in connection with the presently described invention. [0019]
  • Systems as introduced in the Summary of the Invention are described in detail below. The subject multilumen catheters will be described first, both generally and in terms of the figures, followed by a description of the subject systems, kits and representative methods in which the catheters, systems and kits find use. [0020]
  • Multilumen Catheters [0021]
  • As summarized above, the present invention provides multilumen catheters. Specifically, the subject invention includes three different multilumen catheters, which can be used together as a system to simultaneously flush a vascular site with two distinct fluids. Common features of each catheter of the subject invention are that they include a proximal end and a distal end separated by an elongated non-coaxial multilumen tube. By non-coaxial multilumen tube, it is meant a tube that includes at least two lumens which are non-coaxial, i.e., they do not share a common axis. The number of lumens in the multilumen tube may vary, but generally is 2 to 5, and is often 2 to 4, where in certain embodiments the number is 2 or 3. By elongated, it is meant that the distance between the proximal and distal ends is sufficient for the catheter to be inserted or introduced into the vascular system of a patient at a site remote from the vascular lesion that is to be treated through action of the distal end of the catheter, as is known in the art. Catheters intended for intravascular introduction will typically have a length in the range from 50 cm to 200 cm and an outer diameter in the range from 1 French (0.33 mm; Fr.) to 12 Fr., usually from 3 Fr. to 9 Fr. In the case of coronary catheters, the length is typically in the range from 125 to 200 cm, the diameter is preferably below 8 Fr., more preferably below 7 Fr., and most preferably in the range from 2 Fr. to 7 Fr. In certain embodiments, the elongated tubular element has a length of from about 80 to 200 cm, usually from about 90 to 180 cm and more usually from about 90 to 140 cm. [0022]
  • All of the subject multilumen catheters are further characterized in that they include a multiport manifold at their proximal ends. By multiport manifold is meant a manifold that includes two or more ports (in addition to the attachment structure of the mannifold to the proximal end of the elongated tube of the catheter), where the number of ports in the manifold may range from 2 to 4, but is generally 2 or 3, depending on the particular multilumen catheter. In addition, at least two of the ports of the multiport manifold preferably have luer valves or analogous means for establishing a sealed fluid communication with the lumen of an external tubular element or analogous fluid conveying means. In many embodiments, a luer valve is present in these ports, where the valve may be a male or female luer valve. Luer valves are disclosed in U.S. Pat. Nos. 6,063,062; 6,039,302; 5,954,313; 5,947,954; 5,788,215; 5,775,671; 5,738,144; 5,549,651; 5,535,785; 5,474,544; 5,441,487; 5,372,143; 5,284,475; the disclosures of which are herein incorporated by reference. As such, where the multiport manifold is a two port manifold, each of the two ports in the manifold will typically have a luer valve. Alternatively, where the multiport manifold is a three port manifold, only two of the three ports may have luer valves or all three ports may have luer valves. [0023]
  • Another common feature of all of the multilumen catheters of the subject invention is that the elongated multilumen tube is typically a polymeric extruded element, which is made up of one or more biocompatible polymers that have been extruded to produce the non-coaxial multilumen tube. Biocompatible polymers of interest include, but are not limited to: polyimide, polyamide, PBAX™, polyethylene, polyisoprene, nylon and the like. [0024]
  • Although each of the disparate multilumen catheters share the above common features, there are differences between the different specific multilumen catheter designs of the subject invention. As such, each specific type of multilumen catheter of the subject invention, e.g., aspiration, total and partial multilumen catheters, will now be described separately in greater detail. [0025]
  • Aspiration Catheter [0026]
  • The first multilumen catheter of the subject invention is identified herein as the aspiration catheter, as it includes the lumen employed for aspiration when the catheter is used in a system for flushing a vascular site with fluid. The aspiration catheter is characterized by having a proximal end and a distal end separated by a non-coaxial two lumen tube, where a three port manifold is present at the proximal end. In the three port manifold, two of the ports, and more specifically the side or offset ports, have luer valves, while the central port has a valve capable of opening and closing around a tubular element, e.g., a catheter, dilator, guidewire, etc., to produce a sealed relationship with the tubular element. In many embodiments, this element is a Touhy-Borst valve or analogous structure, where Touhy-Borst valves are described in U.S. Pat. Nos. 5,795,307 and 5,320,613; the disclosures of which are herein incorporated by reference. [0027]
  • FIGS. 1A and B provide a depiction of a representative aspiration catheter according to the subject invention. In FIG. 1A, [0028] aspiration catheter 10 has proximal end 14 and distal end 12 separated by elongated non-coaxial two lumen tube 16. The length of elongated tube 16 should be long enough to provide for access of the distal end to the target vascular site upon introduction into the host, subject or patient at a remote site, and typically ranges from about 80 to 200 cm, usually from about 90 to 180 cm and more usually from about 90 to 140 cm. The outer diameter of the elongate tubular member 16 may vary depending on the target vascular site for which it is designed to be used. In other words, the outer diameter of the aspiration catheter is selected so as to provide for access of the distal end of the catheter to the vascular site via the vascular system from the remote point of entry, where the outer diameter typically ranges from about 1.0 to 4.0 mm (3 to 12 Fr), usually from about 1.5 to 3.0 mm (4.5 to 9.0 Fr) and more usually from about 1.7 to 2.7 mm (5 to 8 Fr). In the case of coronary catheters, the length is typically in the range from 125 to 200 cm, the diameter is preferably below 8 Fr., more preferably below 7 Fr., and most preferably in the range from 2 Fr. to 7 Fr.
  • The aspiration catheter is further characterized in that one of the two lumens, generally the larger of the two lumens, opens at the distal end, thereby providing a fluid entry site for fluid from the target vascular site to flow into the lumen. In FIG. 1B, this larger lumen is designated [0029] 17. The inner diameter of this lumen at the open distal end and along the entire length of the tube 16 is sufficient to house either a partial or total occlusion multilumen catheter, as described in greater detail below, and remove fluid from the vascular site at the desired rate, e.g., a rate that provides for substantially isometric or isobaric pressure in the vascular site during treatment, through the resultant annular space. This larger lumen 17 is also known as the aspiration lumen. The inner diameter of the aspiration lumen 17, at least at its distal end and generally along the entire length of the aspiration catheter, is sufficient to provide for adequate flow into the lumen of the catheter, and sometimes ranges from about 0.20 to 2.0, usually from about 0.25 to 1.75 and more usually from about 0.35 to 1.5 mm.
  • Also present at the distal end of the [0030] aspiration catheter 10 is a vessel occlusion means 13, where the vessel occlusion means is usually an inflatable balloon. The balloon 13 is one that is inflatable to a volume sufficient to substantially occlude the vessel in which the aspiration catheter is positioned, e.g., by pressing against the intimal surface of the vessel in which the aspiration catheter is positioned. The inflated balloon diameter generally ranges from about 2 to 30 mm, usually from about 5 to 20 mm. The inflated balloon length typically ranges from about 10 to 30 mm, usually from about 15 to 20 mm. The balloon is in fluid or gaseous communication with an inflation lumen 19 which is the other lumen of the two lumen tube and runs the length of the aspiration catheter from the balloon to the proximal end, but does not open up at the distal end of the catheter. The inflation lumen typically has an inner diameter that ranges from about 0.1 to 0.5 mm, usually from about 0.2 to 0.4 mm. In certain embodiments, the aspiration catheter further includes a separate guidewire lumen (not shown). However, in many embodiments, a separate guidewire lumen is not present.
  • At the [0031] proximal end 14 of aspiration catheter 10 is three port manifold 18. Three port manifold 18 includes side or offset ports 11 a and 11 c, as well as central port 11 b. One of the offset ports, e.g., 11 a is in fluid communication with the smaller lumen 19 and is attached to a balloon inflation means, e.g., a syringe filled with gas or fluid, during use. The other offset port, e.g., 11 c, is in fluid communication the larger aspiration lumen 17 and is attached to a source of negative pressure, e.g., a vacuum, during use. Offset ports 11 a and 11 c are further characterized in having or being in communication with luer valves 15 a and 15 c, respectively. In many embodiments, luer valves 15 a and 15 c are female luer valves. Central port 11 b is in fluid communication with the aspiration lumen 17 and provides the point of access for the total and partial occlusion catheters, described in greater detail below. As such, in the manifold 18 of the aspiration catheter, two of the ports of the manifold, specifically the central port and one of the offset ports, are in fluid communication with the aspiration lumen 17. Central port 11 b is characterized by the presence of Touhy-Borst valve 15 b or an analogous structure. Touhy-Borst valves suitable for use in medical devices, e.g., catheters, are described in U.S. Pat. No. 5,320,613 and 5,795,307.
  • Also present on the catheter shown in FIG. 1A is a [0032] strain relief 18 a. The strain relief protects the proximal end of tube 16 from damage and gives strength to the transition between the tube and manifold 18. The strain relieve locally increases the stiffness of tube 16 to provide a moderated step-wise increase in stiffness from the relatively more flexible tube to the stiffer manifold member. The length of the strain relieve may varies from 5 to 40 mm, but is usually 20 to 30 mm in length. Suitable materials for strain relief 18 a include fluorinated ethylene-propylene or a similar medical grade polymer.
  • The embodiment shown in FIG. 1A includes three-way stop cocks attached to each of the offset ports. These provide for further control of fluid flow into the lumens of the device and/or the introduction of two separate fluids into the same lumen of the device, e.g., an imaging solution into the aspiration lumen and aspiration of fluid through the aspiration lumen, depending on the state of the three way stop-cock. [0033]
  • For convenience during use of the aspiration catheter, each of the ports of the three port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. vacuum source, balloon inflation means, etc. For example, one of the offset ports may have a yellow band, one may have a green band and one may have a red band, thereby uniquely identifying the ports of the three port manifold. [0034]
  • Total Occlusion Multilumen Catheter [0035]
  • Also provided by the subject invention are multilumen catheters that are designed to be inserted inside the aspiration lumen and used to flush a vascular site that is characterized by the presence of a total vascular occlusion, e.g., as shown in FIG. 6 described in greater detail below. These catheters are identified herein as total occlusion catheters. In general, the total occlusion catheters are characterized in that the multilumen tube separating the proximal and distal ends is a two lumen tube. These total occlusion catheters are further characterized in that the multiport manifold is preferably a two port manifold, where both of the ports have luer valves. In certain embodiments, the multilumen total occlusion aspiration catheter further includes a guidewire lumen. [0036]
  • FIGS. 2A and B and C each provide a representation of a total occlusion catheter according to the subject invention. As shown in FIG. 2A, [0037] total occlusion catheter 20 includes proximal end 24 and distal end 22 separated by elongated tubular member 26. Elongated tubular member 26 is sufficiently long to provide for access of the distal end to the target vascular site upon introduction into the host vascular system via a remote entry site of the vascular system. Typically, the length of elongate member 26 ranges from about 90 to 210 cm, usually from about 100 to 190 cm and more usually from about 110 to 150 cm. The outer diameter of the tubular member 26 is such that it may be slidably positioned inside the aspiration lumen of the aspiration catheter, as described above. Typically, the outer diameter of element 26 ranges from about 0.5 to 2.0 (1.5 to 6.0 Fr), usually from about 0.8 to 1.6 mm (2.5 to 5 Fr).
  • [0038] Tubular member 26 is a two lumen tubular member, where the lumens of the catheter are non-coaxial. Each of the lumens, 25 and 27, open at the distal end of catheter 20. One of the lumens is designed to carry a first fluid and the other is designed to carry a second fluid. In many embodiments, the first fluid is a dissolution fluid and the second fluid is a dissolution fluid attenuating fluid, as described in greater detail below. The configuration of the each of the lumens in the embodiment shown in FIG. 2A can be seen in FIG. 2B, which is a cross section of tubular member 26 taken at line A-A shown in FIG. 2A. As can be seen in the representative embodiment, lumen 25 has a substantially circular configuration while lumen 27 has a crescent configuration so as to share a common wall or border with a substantial portion of lumen 25, where by “substantial portion” is meant at least 25%, usually at least 35% and more usually at least 50% of the circumference of lumen 25, where in certain embodiments this portion may be much higher, e.g., 60%, 75% etc. Lumen 25 is typically employed for conveying the dissolution fluid while lumen 27 is typically employed for conveying the dissolution fluid attenuating fluid during use. In FIG. 2C, the cross sectional view show a three lumen total occlusion catheter, where lumen 25 a is employed for dissolution solution, lumen 27 is employed for dissolution fluid attenuating fluid delivery and lumen 29 is the guidewire lumen.
  • The inner diameter of [0039] lumen 25 typically ranges from about 0.2 to 1.0 mm, usually from about 0.2 to 0.7 mm and more usually from about 0.3 to 0.4 mm, so as to provide for a cross-sectional area of about 0.03 to 0.8 mm2, usually from about 0.03 to 0.4 mm2 and more usually from about 0.07 to 0.2 mm2. The cross-sectional area of lumen 27 typically ranges from about 0.03 to 0.8 mm2, usually from about 0.03 to 0.4 mm2 and more usually from about 0.07 to 0.2 mm2. While the configuration of FIG. 2B shows a circular and crescent shaped lumen, other configurations are also possible, e.g., two circular lumens, to semicircular lumens, etc.
  • Also present on the preferred total occlusion catheter at [0040] proximal end 24 is two port manifold 28. Two port manifold 28 includes side or offset port 21 a and central port 21 b. Port 21 a includes female luer valve 23 a while port 23 b includes high pressure female luer valve 23 b. During use, side or offset port 21 a is typically in fluid. communication with a source of dissolution fluid attenuating fluid, e.g., buffer, while central port 23 b is typically in fluid communication with a source of dissolution fluid, e.g., acid solution.
  • Also present on the catheter shown in FIG. 2A is a [0041] strain relief 28 a. It functions as described in connection with strain relief 18 a. In the embodiment shown in FIG. 2A, also present is three-way stop cock attached to the central port which provides for further control of fluid flow into the central lumens of the device, the introduction of two separate fluids into the same lumen of the device and/or the introduction of separate fluids for intermittent flushing, e.g. with heparinized saline, typically used to keep lumens clear and prevent clotting.
  • For convenience during use of the aspiration catheter, each of the ports of the two port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. dissolution fluid reservoir, dissolution fluid attenuating fluid reservoir, etc. For example, one of the offset ports may have a yellow band and one may have a red band, thereby uniquely identifying the ports of the manifold. [0042]
  • Partial Occlusion Catheter [0043]
  • Also provided by the subject invention are multilumen catheters that are designed to be inserted inside the aspiration lumen and used to flush a vascular site that is characterized by the presence of a partial vascular occlusion. These catheters are identified herein as partial occlusion catheters. In general, the partial occlusion catheters are characterized in that the multilumen tube separating the proximal and distal ends is a three lumen tube. These partial occlusion catheters are further characterized in that the multiport manifold is a three port manifold, where each of the ports has a luer valve or analogous structure. In addition to the above features, the partial occlusion catheter also includes a balloon or analogous vessel occlusion means at its distal end and multiple ports proximal to the balloon, where a portion of these infusion ports are in fluid communication with one of the lumens and the remainder are in fluid communication with another of the lumens. In certain embodiments, the partial occlusion catheters of the subject invention further include a guidewire lumen, bring the total number of lumens in the partial occlusion catheter to four. [0044]
  • FIGS. 3A, B and C provide a representation of a partial occlusion catheter according to the subject invention. As shown in FIG. 3A, [0045] partial occlusion catheter 30 includes distal end 32 and proximal end 34 separated by three lumen tube 36. The length of the tubular member 36 generally ranges from about 90 to 250 cm, usually from about 100 to 230 cm and more usually from about 110 to 190 cm. The outer diameter of the tubular member 36 is such that the partial occlusion catheter 30 may be slidably positioned in the aspiration lumen of the aspiration catheter. As such, the outer diameter of tubular member 36 typically ranges from about 0.5 to 2.0, usually from about 0.8 to 1.6 mm.
  • Located at the distal end of [0046] catheter 30 is balloon 31 or analogous occlusion means. The balloon is generally one that is inflatable to a diameter ranging from about 2 to 15 mm, usually about 5 to 10 mm, and typically has a length of from about 10 to 30 mm, usually from about 15 to 20 mm. Proximal to the balloon 31 are a series of ports 43, 45 and 47 which provide for fluid transfer between the outside of tube 36 and the lumens located inside the device. Typically, ports 43 and 45 are in fluid communication with a first lumen inside the tube 36 that is carrying dissolution fluid attenuating fluid while port 47 is in fluid communication with the lumen of the device carrying the dissolution fluid. The diameter of the infusion ports may vary, but typically ranges from about 0.2 to 1.2, usually from about 0.4 to 1.0 and more usually from about 0.5 to 0.8 mm.
  • A representative configuration of the three lumens of [0047] multilumen tube 36 is shown in FIG. 3B, which shows the cross section of tube 36 taken along line A-A as shown in FIG. 3A. As shown in FIG. 3B, lumen 37 has a substantially circular cross section, while lumens 39 and 41 together make up a crescent shape that shares a border with lumen 37 that extends for a substantial portion of the perimeter of lumen 37. The crescent shape made through combination of lumens 39 and 41 is divided to provide for distinct lumens 39 and 41. The diameter of lumen 37 typically ranges from about 0.02 to 1.0 mm, usually from about 0.2 to 0.7 mm and more usually from about 0.3 to 0.4 mm to provide a cross-sectional area ranging from about 0.03 to 0.8 mm2, usually from about 0.03 to 0.4 mm2. The cross sectional area of lumen 39 typically ranges from about 0.03 to 0.8 mm2, usually from about 0.03 to 0.4 mm2 while the cross-sectional area of lumen 41 typically ranges from about 0.05 to about 0.3, usually from about 0.1 to about 0.2. In many embodiments, lumen 37 conveys dissolution fluid attenuating fluid, e.g., buffer, and/or provides for guidewire use, lumen 39 conveys dissolution fluid, e.g., acid, and lumen 41 conveys inflation medium, e.g., gas or fluid, to the balloon. While one type of configuration of the various lumens is shown, other non-coaxial configurations are also possible, e.g., three separate circles, a circle and two distinct crescent shapes, etc., where all of these potential configurations are within the scope of the invention. FIG. 3C provides a cross-section view of an embodiment that includes a guidewire lumen. As such, in FIG. 3C one can see the balloon lumen 41, the dissolution fluid and dissolution fluid conveyance lumens, 39 and 37 a, as well as the guidewire lumen 42.
  • Located at the proximal end [0048] 34 of catheter 30 is three port manifold 38. Three port manifold 38 includes two offset or side ports 33 a and 33 c, which flank central port 33 b. Each of the ports includes a female luer valve, 35 a, 35 b and 35 c. The central port 33 b is typically in fluid communication with a dissolution fluid attenuating fluid source during use. Offset port 33 a is typically in fluid communication with a source of dissolution fluid. Offset port 33 c is typically in fluid communication with a balloon inflation means, e.g., a syringe filled with a gas or liquid.
  • Also present on the catheter shown in FIG. 3A is a [0049] strain relief 38 a. It functions in the manner of strain relief 18 a and 28 a.
  • In the embodiment shown in FIG. 3A, also present are three-way stop cocks attached to each of the offset ports, which elements provide for further control of fluid flow into the lumens of the device, the introduction of two separate fluids into the same lumen of the device and/or the introduction of separate fluids for intermittent flushing, e.g. with heparinized saline, typically used to keep lumens clear and prevent clotting, depending on the state of the three way stop-cock. [0050]
  • For convenience during use of the aspiration catheter, each of the ports of the three port manifold may be uniquely identified, e.g., color coded, so that it is readily apparent as to the element that the port should be connected during use of the device, e.g. vacuum dissolution fluid, dissolution fluid attenuating fluid, balloon inflation means, etc. [0051]
  • Systems [0052]
  • Also provided by the subject invention are systems for flushing a vascular site with two different fluids. By flushing a vascular site is meant introducing fluid into and removing fluid from a vascular site at substantially the same time such that the vascular site remains substantially stable in terms of pressure, e.g., is isobaric, where the pressure changes that occur in the vascular site do not exceed in magnitude a value of about 50 mm Hg and usually do not exceed about 30 mm Hg. Accordingly, maximum pressure will typically remain below about 400 mm Hg, preferably about 100 mm Hg. [0053]
  • The subject systems are characterized by having an aspiration catheter and one of the total or partial occlusion catheters of the subject invention in a nested configuration, such that the total or partial occlusion catheter is slidably positioned inside the aspiration lumen of the aspiration catheter. FIG. 4 provides a representation of a system designed for use with a total occlusion which is made up of a [0054] total occlusion catheter 20 inserted into the aspiration lumen of an aspiration catheter. FIG. 5 provides a representation of a system designed for use in the treatment of a partial occlusion, where the system is made up of a partial occlusion catheter inserted into the aspiration lumen of an aspiration catheter. Because the central manifold port of the aspiration catheter may have a Touhy-Borst valve, a fluid seal can be produced at the interface between the aspiration manifold central port and the outer surface of the partial or total occlusion catheter when inserted into the aspiration lumen of the aspiration catheter.
  • In using the total occlusion catheter system of the subject invention, one of the offset ports of the aspiration manifold is often in fluid communication with a syringe balloon inflation means and the other offset port of the aspiration manifold is in fluid communication with a vacuum source to provide the force for removing fluid from the vascular site via the aspiration lumen. The central port of the total occlusion manifold is in fluid communication with a source of dissolution fluid, e.g., an ENDoFLATOR®, etc., while the offset port of the total occlusion manifold is in fluid communication with a source of dissolution fluid attenuating fluid, e.g., an ENDoFLATOR®, etc. [0055]
  • In using the partial occlusion catheter system according to the subject invention, one of the offset ports of the aspiration manifold is often in fluid communication with a balloon inflation mechanism, e.g., a fluid or gas filled syringe, and the other offset port of the aspiration manifold is in fluid communication with a vacuum source. The central port of the partial occlusion manifold is in fluid communication with a source of dissolution fluid attenuating fluid, e.g., an ENDoFLATOR® filled with dissolution fluid attenuating fluid, while one of the offset ports is in fluid communication with a source of dissolution fluid, e.g. an ENDoFLATOR® filled with dissolution fluid, and the other offset port is in fluid communication with a balloon inflator, e.g. a fluid or gas filled syringe. In use, each of the catheters are filled with the respective solutions for which sources are provided. Furthermore, balloons provided will be at least partially filled, together with adjacent feed lumen in use. The aspiration lumen may also be subject to at least partial vacuum. [0056]
  • Methods [0057]
  • The subject systems find use in applications where it is desired to simultaneously flush a vascular target site with two different fluids. As mentioned above, by flush it is meant that the fluid is introduced into the vascular site and removed from the vascular site is accomplished in manner such that the vascular site remains at substantially constant pressure. However, the pressure throughout the treatment site is predicted to be, on average, lower than the backbleed pressure, i.e., the blood pressure on the proximal side of the aspiration catheter balloon. While the subject systems can, in principle, be employed to flush a vascular site with any two fluids, they are particularly suited for use in applications where chemical tissue ablation at a target vascular site is desired. As such, the subject systems find particular use in the treatment of vascular lesions or obstructions, where the target lesions or obstructions may be organic, inorganic or composite structures of both organic and inorganic components. In such embodiments, the systems are used to flush the target vascular site, and therefore the lesion or obstruction located therein, with a dissolution fluid and a dissolution fluid attenuating fluid. [0058]
  • In these embodiments of the subject methods, the first step is generally to provide for an entry site for the catheter into the vascular system of the host. Entry is typically provided by placement of an introducer sheath at a convenient location, e.g. leg etc., as is known in the art. A guidewire is then inserted through the entry sheath and its distal end is placed at the target vascular site. The aspiration catheter with a dilator present in the central lumen is then moved over the guidewire, where the guidewire generally passes through the central lumen, so that the distal end of the aspiration catheter reaches the target vascular site. Following placement of the distal end of the aspiration catheter at the target vascular site and subsequent deployment of the vascular occlusion means, the dilator is removed and replaced with either the partial or total occlusion catheter inserted through the Touhy-Borst valve of the aspiration manifold central port and into the aspiration lumen. This catheter insert is then moved through the lumen, optionally over the guidewire if still present, until the distal end of the insert is beyond the distal end of the aspiration catheter. In many embodiments, the distal end of the insert will extend some distance beyond the distal end of the aspiration catheter, where this distance typically does not exceed about 20 cm and usually does not exceed about 5 mm. [0059]
  • Upon positioning of the catheter system as described above and deployment of any vascular occlusion means, the dissolution fluid and dissolution fluid attenuating fluid are introduced into the vascular site via the appropriate lumens inside the catheter insert and fluid is removed from the vascular site via the aspiration lumen of the aspiration catheter, and specifically through the annular space present in the system bordered by the inner wall of the aspiration lumen and the outer wall of the catheter insert. The nature of the dissolution fluid and the dissolution fluid attenuating fluid necessarily depends on the nature of the target lesion to be treated. For example, for organic matter comprising lesions, organic matter dissolution fluids (and their companion attenuating fluids) are of interest, such as those described in U.S. patent application Ser. No. 09/528,576; the disclosure of which is herein incorporated by reference. In other embodiments where the target lesion comprises inorganic matter, acidic dissolution solutions and their companion buffer attenuating fluids are of interest, such as those described in WO 00/03651; the disclosure of the priority document of which is herein incorporated by reference. See e.g., WO 00/03651; WO 01/13985; WO 01/15767; WO 01/39783; WO 01/70320; and WO 02/15958; the disclosures of the priority documents of which are herein incorporated by reference. [0060]
  • In many embodiments, the dissolution fluid employed in the subject methods is an inorganic matter dissolution solution. In many of these embodiments, the inorganic matter dissolution fluid is an acidic dissolution fluid. A variety of different types of acidic dissolution solutions may be employed in the subject methods. The acidic treatment solutions that find use in the subject methods generally have a pH of less than about 6.5, where the pH is usually less than about 4.0 and more usually less than about 3.0. In many preferred embodiments, the pH ranges from 0 to 2, and usually 0 to 1. The acidic treatment solution can include a number of different types of acids, where the acids may or may not include a hydrocarbon moiety, i.e., a hydrogen bonded directly to a carbon atom. Suitable acids that lack a hydrocarbon moiety include halogen acids, oxy acids and mixtures thereof, where specific acids of interest of this type include, but are not limited to, hydrochloric, nitric, sulfuric, phosphoric, hydroboric, hydrobromic, carbonic and hydroiotic acids. For such acids, the acid can be a concentrated acid, or can be diluted. Upon dilution, the concentration of an inorganic acid will generally be from about 10 N to about 0.01 N, preferably between 5 N to 0.1 N. Also of interest are acids that include a hydrocarbon moiety, where such acids include, but are not limited to, any organic acid of one to six (C[0061] 1 to C6) carbons in length. Organic acids of this type include, but are not limited to, formic, acetic, propionic, maleic, butanoic, valeric, hexanoic, phenolic, cyclopentanecarboxylic, benzoic, and the like. For an organic acid, the acid can be in concentrated form, or can be diluted. The acidic treatment solution can be composed of either a monobasic or a polybasic acid. Acids are “monobasic” when they have only one replaceable hydrogen atom and yield only one series of salts (e.g., HCl). Acids are “polybasic” when they contain two or more hydrogen atoms which may be neutralized by alkalies and replaced by organic radicals.
  • In many embodiments of the subject invention, the acid solution is hypertonic, by which is meant that the osmolarity of the solution is greater than that of whole blood, i.e. the osomolarity is greater than 300 mosmol. The solution may be rendered hypertonic by including any convenient component or components in the solution that provide for the desired elevated osmolarity. [0062]
  • Any convenient agent that is capable of increasing the osmolarity of the solution may be employed, where suitable agents include salts, sugars, and the like. In many embodiments, the agent that is employed to render the solution hypertonic is one or more, usually no more than three, and more usually no more than two, different salts. Generally, the salt concentration in these embodiments of the solution is at least about 100 mosmol, usually at least about 200 mosmol and more usually at least about 300 mosmol, where the concentration may be as high as 3000 mosmol or higher, depending on the particular salt being employed to render the solution hypertonic, where the solution may be saturated with respect to the salt in certain embodiments. Salts that may be present in the subject solutions include: NaCl, MgCl[0063] 2, Ringers, etc. where NaCl is preferred in many embodiments.
  • Of particular interest in many embodiments is the use of a hydrogen chloride solution. In hydrogen chloride solutions that find use in the subject invention, the concentration of HCl in the solution ranges from about 0.001 to 1.0 N, usually from about 0.01 to 1.0 N and more usually from about 0.1 to 1.0 N. In many embodiments, the hydrogen chloride solution will further include one or more salts which make the solution hypertonic, as described above. In certain preferred embodiments, the salt is NaCl, where the concentration of NaCl in the solution is at least 0.05 M, usually at least 0.10 M, and more usually at least 0.15 M, where the concentration may be as high as 0.25 M or higher. In certain embodiments, the solution will be saturated with NaCl. [0064]
  • Of particular interest are aqueous hydrogen chloride solutions that consist of water, hydrogen chloride and NaCl. The concentration of hydrogen chloride in these solutions of particular interest ranges from about 0.01 to 1.0 N, usually from about 0.05 to 0.5 N and more usually from about 0.075 to 0.25 N. The concentration of NaCl in these solutions of particular interest ranges from about 0.05 to 0.25 M, usually from about 0.05 to 0.10 M. [0065]
  • In certain embodiments, one or more of the delivery fluids is present at a temperature that is less than room temperature. For example, in certain embodiments, the one or more treatment solutions, as described above, is present at a temperature ranging from about 0 to about 20° C., sometimes from about 0 to 15° C., e.g., from about 0 to 10° C. Such embodiments include applications where it is desired to limit restinosis by employing reduced temperature, e.g., cold, solutions. [0066]
  • FIG. 6 provides a representation of the distal end of a total occlusion catheter system flushing a target vascular site with an acidic dissolution fluid and a buffer dissolution fluid attenuating fluid. In FIG. 6, the target vascular site [0067] 61 is shown with total vascular occlusion 62. The distal end of total occlusion catheter system 60 is shown with aspiration catheter 10 and total occlusion catheter 20 extending beyond the end of aspiration catheter 10. Acidic dissolution fluid 63 exits lumen 25 while buffer dissolution fluid attenuating fluid 64 exits lumen 27. Fluid comprising acid, buffer and dissolved plaque, i.e., 65, is withdrawn from the vascular site by the annular opening of the aspiration lumen of the aspiration catheter.
  • The target vascular site is flushed with the dissolution and dissolution fluid attenuating fluids for a period of time sufficient to result in the desired amount of treatment, e.g., target lesion size reduction, enhancement or establishment of fluid flow through the target site, etc. Following the desired amount of treatment, the system is removed from the host. More specific detail regarding the methods in which the subject systems find use can be found in U.S. Pat. No. 09/528,576; the disclosure of which is herein incorporated by reference; and publication no. WO 00/03651 the disclosure of the priority document of which is herein incorporated by reference. [0068]
  • In certain embodiments, external energy is applied to the target aortic valve to promote mechanical break-up of the calcified deposits into particles or debris that can be easily removed from the vascular site. Any means of applying external energy to the aortic valve may be employed. As such, jets or other such means the device which are capable of providing varying external forces to the target deposits cause the target deposit to break up or disrupt may be employed. Of particular interest in many embodiments is the use of sonic energy, e.g., ultrasound. Another means that may be employed to apply external energy to the lesion during the dissolution process is to use a mechanical means of applying external energy. Mechanical means of interest include moving structures, e.g. rotating wires, guidewires, which physically contact the target lesion and thereby apply physical external energy to the target lesion. [0069]
  • Kits [0070]
  • Also provided by the subject invention are kits for use in flushing a vascular site with two fluids. The subject kits at least include the components of a partial occlusion or total occlusion catheter system according to the subject invention. As such, the kits include an aspiration catheter and at least one of a partial occlusion catheter and a total occlusion catheter. In many embodiments, the kits include both a partial occlusion catheter and a total occlusion catheter. The subject kits may also include a dissolution fluid and/or dissolution fluid attenuating fluid, or components/precursors thereof, where representative dissolution fluids and dissolution fluid attenuating fluids are disclosed above. The dissolution fluids and dissolution fluid attenuating fluids or component(s) thereof are present in the kit in a suitable container, e.g., a bottle, pouch, fluid filled Endeflator, etc. which is capable of serving as a storage vessel for the this component of the kit and, preferably, capable of preserving the sterility of this component of the kit, as this component of the kit is preferably sterile, e.g., medical grade. [0071]
  • The kits of the subject invention may also include a number of different optional components, which components may find use in methods in which the subject kit components are employed. One optional component that may be present in the subject kits is a guidewire. Any convenient type of guidewire may be present, where a number of different guidewires are known to those of skill in the art. Guidewires of interest include those described in U.S. Pat. Nos. 6,007,514; 5,980,471; 5,957,865; 5,938,609; 5,931,819; 5,916,178; 5,908,395; 5,902,254; 5,865,767; 5,827,201; 5,788,654; 5,772,609; 5,769,796; 5,755,695; 5,749,837; 5,682,897; 5,660,180; 5,636,642; 5,606,981; 5,599,492; 5,596,996; 5,558,093; 5,546,948; 5,520,189; 5,507,301; 5,497,782; D363,776; 5,460,187; 5,441,497; 5,437,288; 5,427,118; 5,421,349; 5,411,033; 5,409,015; 5,368,035; 5,341,818; 5,339,833; 5,313,967; 5,303,714; RE34,466; 5,265,622; 5,238,005; 5,184,621; 5,167,239; 5,147,317; 5,144,959; 5,111,829; 5,107,852; 5,095,915; 5,095,911 5,084,022; 5,069,226; 5,063,935; 4,966,163; 4,953,553; 4,875,489; 4,827,941; 4,811,743; 4,676,249; 4,534,363; 4,080,706 and 4,003,369; the disclosures of which are herein incorporated by reference. Also of interest are dilators for use in creating entries into the vascular system of the host. [0072]
  • Additional optional components that may be present in kits of the subject invention include various fluids and solutions in addition to the dissolution fluid and dissolution fluid attenuating fluid described above. Additional fluids that may be present include: organic matter dissolution fluids, wash or rinsing fluids, imaging agent fluid mediums that include an imaging agent, such as a non-ionic imaging agents, e.g., CONRAY™, OXILAN™, fluids containing one or more pharmacological agents, e.g., agents that promote healing, reduce inflammation, and the like; etc. [0073]
  • Other components that may be present in the subject kits include one or more additional components and accessories for use with the fluid delivery means present in the kit, including tubing for connecting the various catheter components with fluid reservoirs, syringes, pumps, etc., connectors, stop-cocks, dilators, insertion sheaths, vacuum regulators, negative pressure or vacuum generators/sources, luer valve adapters, etc. [0074]
  • In addition to above mentioned components, the subject kits typically further include instructions for using the components of the kit to flush a vascular site with two different fluids, e.g., to flush a vascular site with a dissolution fluid and a dissolution fluid attenuating fluid. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate. [0075]
  • It is evident from the above discussion that the catheters and systems that are made up of the same provide a reliable and convenient way to flush a target vascular site with two different fluids. Because the catheter devices have a design that allows them to be produced via extrusion technology using polymeric materials, they may be economically produced and the number of different working elements is kept to a minimum. In view of these factors and such others discussed above, the subject kits represent a significant contribution to the art. [0076]
  • All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. [0077]
  • Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. [0078]

Claims (24)

1. A multilumen catheter comprising:
(a) a proximal end;
(b) a distal end; and
(c) a multiport manifold located at said proximal end, wherein:
(i) said multiport manifold comprises at least two ports having luer valves; and
(ii) said proximal and distal ends are separated by a non-coaxial multilumen tube.
2. The multilumen catheter according to claim 1, wherein said multiport manifold comprises three ports and said multilumen tube comprises two lumens.
3. The multilumen catheter according to claim 2, wherein a first port of said three port manifold comprises a Touhy-Borst valve and the remaining two ports of said three port manifold comprise luer valves.
4. The multilumen catheter according to claim 3, wherein a vascular occlusion mechanism is associated with said distal end.
5. The multilumen catheter according to claim 4, wherein said vascular occlusion mechanism is a balloon.
6. The multilumen catheter according to claim 4, wherein the diameter of one of said two lumens is substantially larger than the diameter of the other of said two lumens.
7. The multilumen catheter according to claim 6, wherein two of said ports of said three port manifold are in fluid communication with said lumen of larger diameter.
8. The multilumen catheter according to claim 7, wherein one of said ports in fluid communication with said larger diameter lumen is said port comprising a Touhy-Borst valve.
9. The multilumen catheter according to claim 1, wherein said multiport catheter is a two port catheter and said multilumen tube comprises two lumens.
10. The multilumen catheter according to claim 9, wherein said luer valves are female luer valves.
11. The multilumen catheter according to claim 9, wherein one of said two lumens has a substantially circular cross section while the other of said two lumens has a substantially non-circular cross section.
12. The multilumen catheter according to claim 1 1, wherein said non-circular cross section lumen has a crescent shaped cross-section.
13. The multilumen catheter according to claim 12, wherein said lumen having a crescent shaped cross section is positioned in said tube so as to be adjacent to at least 50% of the perimeter of said lumen having a substantially circular cross-section.
14. A multilumen catheter according to claim 1, wherein said multiport manifold is a three port manifold and said multilumen tube comprises three lumens.
15. The multilumen catheter according to claim 14, wherein each of said three ports of said three port manifold comprises a luer valve.
16. The multilumen catheter according to claim 15, wherein said luer valves are female luer valves.
17. The multilumen catheter according to claim 14, wherein a vascular occlusion mechanism is associated with said distal end.
18. The multilumen catheter according to claim 17, wherein said vascular occlusion mechanism is a balloon.
19. The multilumen catheter according to claim 14, wherein one of said lumens of said three lumen tube has a substantially circular cross section while the remaining two lumens have substantially non-circular cross sections.
20. The multilumen catheter according to claim 19, wherein said catheter comprises at least two ports at said distal end to provide for the exit of fluid from said lumen having a substantially circular cross section.
21-43. (Canceled).
44. A system for flushing a vascular site, said system comprising:
(I) a first two lumen catheter comprising:
(A) a proximal end;
(B) a distal end; and
(C) a three port manifold located at said proximal end, wherein:
(i) said three port manifold comprises at least two offset ports having luer valves and a central port comprising a Touhy-Borst valve; and
(ii) said proximal and distal ends are separated by a non-coaxial two lumen tube; and
(II) a second multilumen catheter inserted inside of one of said two lumens of said first two lumen catheter; wherein said second multilumen catheter is a catheter selected from the group consisting of:
(A) a two lumen catheter comprising:
(i) a proximal end;
(ii) a distal end; and
(iii) a two port manifold located at said proximal end, wherein each port of said two port manifold comprises a luer valve; and said proximal and distal ends are separated by a non-coaxial two lumen tube; and
(B) three lumen catheter comprising:
(i) a proximal end;
(ii) a distal end; and
(iii) a three port manifold located at said proximal end, wherein, each port of said three port manifold comprises a luer valve; and said proximal and distal ends are separated by a non-coaxial three lumen tube.
45-57. (canceled).
58. A kit for using in flushing a vascular site with fluid, said kit comprising:
(I) a first two lumen catheter comprising:
(A) a proximal end;
(B) a distal end; and
(C) a three port manifold located at said proximal end, wherein:
(i) said three port manifold comprises at least two offset ports having luer valves and a central port comprising a Touhy-Borst valve; and
(ii) said proximal and distal ends are separated by a non-coaxial two lumen tube; and
(II) at least one second multilumen catheter selected from the group consisting of:
(A) a two lumen catheter comprising:
(i) a proximal end;
(ii) a distal end; and
(iii) a two port manifold located at said proximal end, wherein:
(a) each port of said two port manifold comprises a luer valve; and
(b) said proximal and distal ends are separated by a non-coaxial two lumen tube; and
(B) a three lumen catheter comprising:
(i) a proximal end;
(ii) a distal end; and
(iii) a three port manifold located at said proximal end, wherein;
(a) each port of said three port manifold comprises a luer valve; and
(b) said proximal and distal ends are separated by a non-coaxial three lumen tube.
US10/771,160 2002-03-18 2004-02-02 Multilumen catheters and methods for their use Abandoned US20040220515A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/771,160 US20040220515A1 (en) 2002-03-18 2004-02-02 Multilumen catheters and methods for their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/101,544 US6712798B2 (en) 2002-03-18 2002-03-18 Multilumen catheters and methods for their use
US10/771,160 US20040220515A1 (en) 2002-03-18 2004-02-02 Multilumen catheters and methods for their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/101,544 Continuation US6712798B2 (en) 2002-03-18 2002-03-18 Multilumen catheters and methods for their use

Publications (1)

Publication Number Publication Date
US20040220515A1 true US20040220515A1 (en) 2004-11-04

Family

ID=28452332

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/101,544 Expired - Lifetime US6712798B2 (en) 2002-03-18 2002-03-18 Multilumen catheters and methods for their use
US10/771,160 Abandoned US20040220515A1 (en) 2002-03-18 2004-02-02 Multilumen catheters and methods for their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/101,544 Expired - Lifetime US6712798B2 (en) 2002-03-18 2002-03-18 Multilumen catheters and methods for their use

Country Status (7)

Country Link
US (2) US6712798B2 (en)
EP (1) EP1490130A4 (en)
JP (1) JP4413625B2 (en)
AU (1) AU2003225914B2 (en)
CA (1) CA2479753C (en)
NZ (5) NZ562816A (en)
WO (1) WO2003080151A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197956A1 (en) * 2006-02-23 2007-08-23 Possis Medical, Inc. Dual lumen aspiration catheter system
WO2010096165A1 (en) * 2009-02-18 2010-08-26 Loay Salman Catheter flushing assembly
US20110282377A1 (en) * 2005-06-22 2011-11-17 Pepper Lanny R Balloon dilation catheter having transition from coaxial lumens to non-coaxial multiple lumens
US20130310806A1 (en) * 2011-07-17 2013-11-21 Turbo Seal L.P. Nasogastric Tube
US20140188080A1 (en) * 2011-07-17 2014-07-03 Turbo Seal L.P. Nasogastric tube
US9827169B2 (en) 2011-07-17 2017-11-28 Nutriseal L.P. Nasogastric tube with camera
US20180049950A1 (en) * 2015-02-02 2018-02-22 Nutriseal L.P. Enteral feeding pump
US10350145B2 (en) 2011-07-17 2019-07-16 Envizion Medical Ltd. Nasogastric tube
US10695269B2 (en) 2014-08-14 2020-06-30 Envizion Medical Ltd. Nasogastric tube
WO2021250668A1 (en) * 2020-06-10 2021-12-16 Magna Mater Medical Ltd. Device and method for oocyte retrieval from fallopian tubes
US11207456B2 (en) * 2012-07-10 2021-12-28 Valorisation Recherche Hscm, Limited Partnership Method and device for infusion of pharmacologic agents and thrombus aspiration in artery

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769853B2 (en) * 1999-06-11 2004-02-05 Atossa Genetics, Inc. Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue
US6758836B2 (en) * 2002-02-07 2004-07-06 C. R. Bard, Inc. Split tip dialysis catheter
EP1483008B1 (en) * 2002-03-09 2008-02-20 BRODERSEN, Jens P. Sclerosing catheter for sclerosing blood vessels, especially veins
US6712798B2 (en) * 2002-03-18 2004-03-30 Corazon Technologies, Inc. Multilumen catheters and methods for their use
US7393339B2 (en) 2003-02-21 2008-07-01 C. R. Bard, Inc. Multi-lumen catheter with separate distal tips
US20050015048A1 (en) 2003-03-12 2005-01-20 Chiu Jessica G. Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof
US7250041B2 (en) 2003-03-12 2007-07-31 Abbott Cardiovascular Systems Inc. Retrograde pressure regulated infusion
US20040243095A1 (en) 2003-05-27 2004-12-02 Shekhar Nimkar Methods and apparatus for inserting multi-lumen spit-tip catheters into a blood vessel
EP1949933A3 (en) * 2003-12-23 2008-08-06 Cytyc Corporation Medical instrument for accessing a breast duct
AU2005206767B2 (en) * 2004-01-09 2009-09-17 Corazon Technologies, Inc. Multilumen catheters and methods for their use
EP1732637B1 (en) * 2004-01-09 2009-08-05 Corazon Technologies, Inc. Multilumen catheters
US20050197644A1 (en) * 2004-03-03 2005-09-08 Waychoff Challen W.Ii Colon hydrotherapy device
US8083728B2 (en) 2004-03-18 2011-12-27 C. R. Bard, Inc. Multifunction adaptor for an open-ended catheter
US7594910B2 (en) * 2004-03-18 2009-09-29 C. R. Bard, Inc. Catheter connector
US7594911B2 (en) * 2004-03-18 2009-09-29 C. R. Bard, Inc. Connector system for a proximally trimmable catheter
US7854731B2 (en) 2004-03-18 2010-12-21 C. R. Bard, Inc. Valved catheter
US7377915B2 (en) 2004-04-01 2008-05-27 C. R. Bard, Inc. Catheter connector system
US8992454B2 (en) 2004-06-09 2015-03-31 Bard Access Systems, Inc. Splitable tip catheter with bioresorbable adhesive
US8323227B2 (en) 2004-07-02 2012-12-04 C. R. Bard, Inc. Tip configurations for a multi-lumen catheter
US20060004316A1 (en) 2004-07-02 2006-01-05 Difiore Attilio E Reduction of recirculation in catheters
US7918787B2 (en) * 2005-02-02 2011-04-05 Voyage Medical, Inc. Tissue visualization and manipulation systems
US8137333B2 (en) 2005-10-25 2012-03-20 Voyage Medical, Inc. Delivery of biological compounds to ischemic and/or infarcted tissue
US11478152B2 (en) 2005-02-02 2022-10-25 Intuitive Surgical Operations, Inc. Electrophysiology mapping and visualization system
US7860556B2 (en) * 2005-02-02 2010-12-28 Voyage Medical, Inc. Tissue imaging and extraction systems
US9510732B2 (en) 2005-10-25 2016-12-06 Intuitive Surgical Operations, Inc. Methods and apparatus for efficient purging
US8078266B2 (en) 2005-10-25 2011-12-13 Voyage Medical, Inc. Flow reduction hood systems
US10064540B2 (en) 2005-02-02 2018-09-04 Intuitive Surgical Operations, Inc. Visualization apparatus for transseptal access
US8050746B2 (en) 2005-02-02 2011-11-01 Voyage Medical, Inc. Tissue visualization device and method variations
US20080015569A1 (en) 2005-02-02 2008-01-17 Voyage Medical, Inc. Methods and apparatus for treatment of atrial fibrillation
US7860555B2 (en) 2005-02-02 2010-12-28 Voyage Medical, Inc. Tissue visualization and manipulation system
US7930016B1 (en) 2005-02-02 2011-04-19 Voyage Medical, Inc. Tissue closure system
WO2006089243A2 (en) * 2005-02-16 2006-08-24 University Of Virginia Patent Foundation Blood flow bypass catheters and methods for the delivery of medium to the vasculature and body ducts
US10362947B2 (en) 2005-03-15 2019-07-30 Integra LifeSciences Switzerland Sarl Pressure sensing devices
US7510533B2 (en) 2005-03-15 2009-03-31 Codman & Shurtleff, Inc. Pressure sensing valve
US7875019B2 (en) 2005-06-20 2011-01-25 C. R. Bard, Inc. Connection system for multi-lumen catheter
US8221310B2 (en) 2005-10-25 2012-07-17 Voyage Medical, Inc. Tissue visualization device and method variations
US9055906B2 (en) 2006-06-14 2015-06-16 Intuitive Surgical Operations, Inc. In-vivo visualization systems
US20080097476A1 (en) 2006-09-01 2008-04-24 Voyage Medical, Inc. Precision control systems for tissue visualization and manipulation assemblies
US10004388B2 (en) 2006-09-01 2018-06-26 Intuitive Surgical Operations, Inc. Coronary sinus cannulation
JP2010502313A (en) * 2006-09-01 2010-01-28 ボエッジ メディカル, インコーポレイテッド Method and apparatus for the treatment of atrial fibrillation
US20100191195A1 (en) * 2006-10-08 2010-07-29 Ira Kirschenbaum Cannulated apparatus and method relating to microfracture and revascularization methodologies
US10335131B2 (en) 2006-10-23 2019-07-02 Intuitive Surgical Operations, Inc. Methods for preventing tissue migration
US20080183036A1 (en) 2006-12-18 2008-07-31 Voyage Medical, Inc. Systems and methods for unobstructed visualization and ablation
US8131350B2 (en) 2006-12-21 2012-03-06 Voyage Medical, Inc. Stabilization of visualization catheters
US8758229B2 (en) 2006-12-21 2014-06-24 Intuitive Surgical Operations, Inc. Axial visualization systems
CA2679405C (en) 2007-02-27 2015-12-22 Erik N. K. Cressman Thermochemical ablation of bodily tissue
WO2008134457A1 (en) 2007-04-27 2008-11-06 Voyage Medical, Inc. Complex shape steerable tissue visualization and manipulation catheter
US8657805B2 (en) 2007-05-08 2014-02-25 Intuitive Surgical Operations, Inc. Complex shape steerable tissue visualization and manipulation catheter
JP2010526598A (en) 2007-05-11 2010-08-05 ボエッジ メディカル, インコーポレイテッド Visual electrode ablation system
FR2916625B1 (en) * 2007-05-31 2010-08-20 Phakos CRYOGENIC DEVICE FOR SURGICAL USE
US20090030276A1 (en) * 2007-07-27 2009-01-29 Voyage Medical, Inc. Tissue visualization catheter with imaging systems integration
US8235985B2 (en) 2007-08-31 2012-08-07 Voyage Medical, Inc. Visualization and ablation system variations
US20090062790A1 (en) * 2007-08-31 2009-03-05 Voyage Medical, Inc. Direct visualization bipolar ablation systems
CN101918066B (en) 2007-10-17 2013-07-31 巴德阿克塞斯系统股份有限公司 Manufacture of split tip catheters and the split tip catheters
US8066660B2 (en) * 2007-10-26 2011-11-29 C. R. Bard, Inc. Split-tip catheter including lateral distal openings
US8292841B2 (en) 2007-10-26 2012-10-23 C. R. Bard, Inc. Solid-body catheter including lateral distal openings
US9579485B2 (en) 2007-11-01 2017-02-28 C. R. Bard, Inc. Catheter assembly including a multi-lumen configuration
CN101918067B (en) 2007-11-01 2013-04-10 C·R·巴德股份有限公司 Catheter assembly including triple lumen tips
US20090125022A1 (en) * 2007-11-12 2009-05-14 Voyage Medical, Inc. Tissue visualization and ablation systems
US20090171323A1 (en) * 2007-12-26 2009-07-02 Cook Incorporated Catheter assembly and fluid supply apparatus therefor
US8858609B2 (en) 2008-02-07 2014-10-14 Intuitive Surgical Operations, Inc. Stent delivery under direct visualization
US7717900B2 (en) * 2008-05-28 2010-05-18 Angio Dynamics, Inc. Locking clamp
US9101735B2 (en) 2008-07-07 2015-08-11 Intuitive Surgical Operations, Inc. Catheter control systems
WO2010014658A1 (en) * 2008-07-31 2010-02-04 Regents Of The University Of Minnesota Thermochemical ablation system using heat from delivery of electrophiles
US8894643B2 (en) 2008-10-10 2014-11-25 Intuitive Surgical Operations, Inc. Integral electrode placement and connection systems
US8333012B2 (en) 2008-10-10 2012-12-18 Voyage Medical, Inc. Method of forming electrode placement and connection systems
EP2348966A4 (en) * 2008-10-24 2012-08-08 Innerspace Inc Catheter with pressure sensor
US9468364B2 (en) 2008-11-14 2016-10-18 Intuitive Surgical Operations, Inc. Intravascular catheter with hood and image processing systems
WO2010151825A1 (en) 2009-06-26 2010-12-29 C. R. Bard, Inc. Proximally trimmable catheter including pre-attached bifurcation and related methods
AU2010324908B2 (en) 2009-11-24 2014-05-15 Regents Of The University Of Minnesota Methods and systems for chemical ablation
US8694071B2 (en) 2010-02-12 2014-04-08 Intuitive Surgical Operations, Inc. Image stabilization techniques and methods
AU2011217844B2 (en) * 2010-02-18 2014-09-25 BiO2 Medical, Inc. Vena cava filter catheter and method
US9814522B2 (en) 2010-04-06 2017-11-14 Intuitive Surgical Operations, Inc. Apparatus and methods for ablation efficacy
USD748252S1 (en) 2013-02-08 2016-01-26 C. R. Bard, Inc. Multi-lumen catheter tip
DE102013225154A1 (en) * 2013-12-06 2015-06-11 Raumedic Ag Catheter tube system and method of making a catheter tube system
WO2016011091A1 (en) 2014-07-14 2016-01-21 C. R. Bard, Inc. Apparatuses, systems, and methods for inserting split tip catheters having enhanced stiffening and guiding features
CA2967015C (en) 2014-11-07 2023-02-28 C.R. Bard, Inc. Connection system for tunneled catheters
DE102015206930A1 (en) * 2015-04-16 2016-10-20 Olympus Winter & Ibe Gmbh Surgical instrument, in particular resectoscope, with a rinsing circuit
FR3056917B1 (en) 2016-09-30 2022-02-11 Vygon SYSTEM FOR INTRODUCING A CATHETER INTO A VEIN
CA3073550A1 (en) 2017-08-23 2019-02-28 C.R. Bard, Inc. Catheter assemblies and methods thereof
WO2019070782A1 (en) 2017-10-03 2019-04-11 Research Development Foundation Systems and methods for coronary occlusion treatment
JP2019097596A (en) * 2017-11-28 2019-06-24 株式会社カネカ Balloon catheter
EP4084695A1 (en) 2019-12-31 2022-11-09 Pandx Ltd Catheter and method for isolating a region in a hollow organ of a mammal, and system based on the catheter, and use of the catheter
WO2023075634A1 (en) 2021-11-01 2023-05-04 Pandx Ltd Stent-like catheter for isolating a region in a hollow organ of a mammal, and system based on the catheter
WO2024033700A1 (en) 2022-08-12 2024-02-15 Pandica Ltd Use of a catheter for isolating a region in a hollow organ of a mammal (variants)

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329994A (en) * 1980-06-18 1982-05-18 American Hospital Supply Corporation Multilumen catheter
US4445892A (en) * 1982-05-06 1984-05-01 Laserscope, Inc. Dual balloon catheter device
US4573966A (en) * 1981-11-24 1986-03-04 Schneider Medintag Ag Method and apparatus for removing and/or enlarging constricted areas in vessels conducting body fluids
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4655746A (en) * 1985-12-02 1987-04-07 Target Therapeutics Catheter device
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4838881A (en) * 1984-05-04 1989-06-13 Deseret Medical, Inc. Multilumen catheter and associated IV tubing
US4886507A (en) * 1988-02-01 1989-12-12 Medex, Inc. Y connector for angioplasty procedure
US4901735A (en) * 1988-10-04 1990-02-20 Peter Von Berg Extrakorporale Systeme - Medizintechnik Gmbh Pressure meter catheter with in-situ zero setting
US4901734A (en) * 1987-08-17 1990-02-20 Nova Medical Specialties Dual-thermistor thermodilution catheter
US4911163A (en) * 1986-06-12 1990-03-27 Ernesto Fina Two ballooned catheter device for diagnostic and operative use
US4976733A (en) * 1988-02-03 1990-12-11 Biomedical Design, Inc. Prevention of prosthesis calcification
US5059178A (en) * 1988-08-03 1991-10-22 Ya Wang D Method of percutaneously removing a thrombus from a blood vessel by using catheters and system for removing a thrombus from a blood vessel by using catheters
US5090960A (en) * 1990-01-12 1992-02-25 Don Michael T Anthony Regional perfusion dissolution catheter
US5149330A (en) * 1991-01-10 1992-09-22 The Kendall Company Catheter convertible from single to multilumen
US5167623A (en) * 1990-12-27 1992-12-01 The Kendall Company Multilumen catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5195955A (en) * 1989-11-14 1993-03-23 Don Michael T Anthony Device for removal of embolic debris
US5207648A (en) * 1990-12-14 1993-05-04 The Kendall Company Multilumen catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
US5380284A (en) * 1993-08-13 1995-01-10 Don Michael; T. Anthony Obstruction dissolution catheter with variably expanding blocking balloons and method of use
US5443446A (en) * 1991-04-04 1995-08-22 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
US5462529A (en) * 1993-09-29 1995-10-31 Technology Development Center Adjustable treatment chamber catheter
US5541937A (en) * 1993-12-27 1996-07-30 Canon Kabushiki Kaisha Apparatus for uniformly correcting erasure and error of received word by using a common polynomial
US5925016A (en) * 1995-09-27 1999-07-20 Xrt Corp. Systems and methods for drug delivery including treating thrombosis by driving a drug or lytic agent through the thrombus by pressure
US6004310A (en) * 1998-06-17 1999-12-21 Target Therapeutics, Inc. Multilumen catheter shaft with reinforcement
US6013068A (en) * 1998-07-28 2000-01-11 Spiegelhalter; Judith A. Variable lumen catheter
US6712798B2 (en) * 2002-03-18 2004-03-30 Corazon Technologies, Inc. Multilumen catheters and methods for their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601701A (en) * 1985-02-25 1986-07-22 Argon Medical Corp. Multi-purpose multi-lumen catheter
US6113576A (en) * 1993-08-04 2000-09-05 Lake Region Manufacturing, Inc. Thrombolysis catheter system with fixed length infusion zone
CA2125258C (en) * 1993-08-05 1998-12-22 Dinah B Quiachon Multicapsule intraluminal grafting system and method
US5542937A (en) 1994-06-24 1996-08-06 Target Therapeutics, Inc. Multilumen extruded catheter
US5788215A (en) * 1995-12-29 1998-08-04 Rymed Technologies Medical intravenous administration line connectors having a luer or pressure activated valve
AU5101699A (en) 1998-07-15 2000-02-07 Corazon Technologies, Inc. Methods and devices for reducing the mineral content of vascular calcified lesions
US6755811B1 (en) 1999-08-25 2004-06-29 Corazon Technologies, Inc. Methods and devices for reducing the mineral content of a region of non-intimal vascular tissue
WO2001015767A1 (en) 1999-08-27 2001-03-08 Corazon Technologies, Inc. Catheter devices and methods for their use in the treatment of calcified vascular occlusions
US6156350A (en) 1999-12-02 2000-12-05 Corazon Technologies, Inc. Methods and kits for use in preventing restenosis
CA2403533C (en) 2000-03-20 2014-12-30 Corazon Technologies, Inc. Methods and systems for enhancing fluid flow through an obstructed vascular site
EP1351723B1 (en) 2000-08-24 2016-02-17 Cordis Corporation Fluid delivery systems for delivering fluids to multi-lumen catheters

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329994A (en) * 1980-06-18 1982-05-18 American Hospital Supply Corporation Multilumen catheter
US4573966A (en) * 1981-11-24 1986-03-04 Schneider Medintag Ag Method and apparatus for removing and/or enlarging constricted areas in vessels conducting body fluids
US4610662A (en) * 1981-11-24 1986-09-09 Schneider Medintag Ag Method for the elimination or the enlargement of points of constriction in vessels carrying body fluids
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4445892A (en) * 1982-05-06 1984-05-01 Laserscope, Inc. Dual balloon catheter device
US4838881A (en) * 1984-05-04 1989-06-13 Deseret Medical, Inc. Multilumen catheter and associated IV tubing
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4655746A (en) * 1985-12-02 1987-04-07 Target Therapeutics Catheter device
US4911163A (en) * 1986-06-12 1990-03-27 Ernesto Fina Two ballooned catheter device for diagnostic and operative use
US4901734A (en) * 1987-08-17 1990-02-20 Nova Medical Specialties Dual-thermistor thermodilution catheter
US4886507A (en) * 1988-02-01 1989-12-12 Medex, Inc. Y connector for angioplasty procedure
US4976733A (en) * 1988-02-03 1990-12-11 Biomedical Design, Inc. Prevention of prosthesis calcification
US5059178A (en) * 1988-08-03 1991-10-22 Ya Wang D Method of percutaneously removing a thrombus from a blood vessel by using catheters and system for removing a thrombus from a blood vessel by using catheters
US4901735A (en) * 1988-10-04 1990-02-20 Peter Von Berg Extrakorporale Systeme - Medizintechnik Gmbh Pressure meter catheter with in-situ zero setting
US5195955A (en) * 1989-11-14 1993-03-23 Don Michael T Anthony Device for removal of embolic debris
US5090960A (en) * 1990-01-12 1992-02-25 Don Michael T Anthony Regional perfusion dissolution catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
US5207648A (en) * 1990-12-14 1993-05-04 The Kendall Company Multilumen catheter
US5167623A (en) * 1990-12-27 1992-12-01 The Kendall Company Multilumen catheter
US5149330A (en) * 1991-01-10 1992-09-22 The Kendall Company Catheter convertible from single to multilumen
US5443446A (en) * 1991-04-04 1995-08-22 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380284A (en) * 1993-08-13 1995-01-10 Don Michael; T. Anthony Obstruction dissolution catheter with variably expanding blocking balloons and method of use
US5462529A (en) * 1993-09-29 1995-10-31 Technology Development Center Adjustable treatment chamber catheter
US5541937A (en) * 1993-12-27 1996-07-30 Canon Kabushiki Kaisha Apparatus for uniformly correcting erasure and error of received word by using a common polynomial
US5925016A (en) * 1995-09-27 1999-07-20 Xrt Corp. Systems and methods for drug delivery including treating thrombosis by driving a drug or lytic agent through the thrombus by pressure
US6004310A (en) * 1998-06-17 1999-12-21 Target Therapeutics, Inc. Multilumen catheter shaft with reinforcement
US6013068A (en) * 1998-07-28 2000-01-11 Spiegelhalter; Judith A. Variable lumen catheter
US6712798B2 (en) * 2002-03-18 2004-03-30 Corazon Technologies, Inc. Multilumen catheters and methods for their use

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110282377A1 (en) * 2005-06-22 2011-11-17 Pepper Lanny R Balloon dilation catheter having transition from coaxial lumens to non-coaxial multiple lumens
US8486103B2 (en) * 2005-06-22 2013-07-16 Bard Peripheral Vascular, Inc. Balloon dilation catheter having transition from coaxial lumens to non-coaxial multiple lumens
US20070197956A1 (en) * 2006-02-23 2007-08-23 Possis Medical, Inc. Dual lumen aspiration catheter system
WO2007100585A3 (en) * 2006-02-23 2008-05-02 Possis Medical Inc Dual lumen aspiration catheter system
US7608063B2 (en) 2006-02-23 2009-10-27 Medrad, Inc. Dual lumen aspiration catheter system
WO2010096165A1 (en) * 2009-02-18 2010-08-26 Loay Salman Catheter flushing assembly
US20100228232A1 (en) * 2009-02-18 2010-09-09 Loay Salman Catheter flushing assembly
US20140188080A1 (en) * 2011-07-17 2014-07-03 Turbo Seal L.P. Nasogastric tube
US20130310806A1 (en) * 2011-07-17 2013-11-21 Turbo Seal L.P. Nasogastric Tube
US9789029B2 (en) * 2011-07-17 2017-10-17 Nutriseal Limited Partnership Nasogastric tube
US9827169B2 (en) 2011-07-17 2017-11-28 Nutriseal L.P. Nasogastric tube with camera
US9839584B2 (en) * 2011-07-17 2017-12-12 Nutriseal Limited Partnership Nasogastric tube
US10350145B2 (en) 2011-07-17 2019-07-16 Envizion Medical Ltd. Nasogastric tube
US10646406B2 (en) 2011-07-17 2020-05-12 Envizion Medical Ltd. Nasogastric tube
US11207456B2 (en) * 2012-07-10 2021-12-28 Valorisation Recherche Hscm, Limited Partnership Method and device for infusion of pharmacologic agents and thrombus aspiration in artery
US10695269B2 (en) 2014-08-14 2020-06-30 Envizion Medical Ltd. Nasogastric tube
US20180049950A1 (en) * 2015-02-02 2018-02-22 Nutriseal L.P. Enteral feeding pump
US10376447B2 (en) * 2015-02-02 2019-08-13 Envizion Medical Ltd. Enteral feeding system with controlled reflux preventive vacuum sealing
WO2021250668A1 (en) * 2020-06-10 2021-12-16 Magna Mater Medical Ltd. Device and method for oocyte retrieval from fallopian tubes

Also Published As

Publication number Publication date
WO2003080151A2 (en) 2003-10-02
NZ562816A (en) 2009-02-28
US20030187411A1 (en) 2003-10-02
JP4413625B2 (en) 2010-02-10
US6712798B2 (en) 2004-03-30
NZ562817A (en) 2009-02-28
NZ535967A (en) 2008-06-30
NZ565804A (en) 2008-08-29
EP1490130A2 (en) 2004-12-29
AU2003225914B2 (en) 2008-09-11
JP2005520642A (en) 2005-07-14
NZ562818A (en) 2008-12-24
WO2003080151A3 (en) 2004-02-05
CA2479753C (en) 2012-05-22
AU2003225914A1 (en) 2003-10-08
CA2479753A1 (en) 2003-10-02
EP1490130A4 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
US6712798B2 (en) Multilumen catheters and methods for their use
US6562020B1 (en) Kits for use in the treatment of vascular calcified lesions
US8728026B2 (en) Devices and methods for treating aortic valve stenosis
US20060200191A1 (en) Method and apparatuses for treating an intravascular occlusion
AU2016244272A1 (en) Apparatus and methods for clot disruption and evacuation
US8303538B2 (en) Rheolytic thrombectomy catheter with self-inflating distal balloon
EP1229959B1 (en) Catheter devices for use in the treatment of calcified vascular occlusions
AU2009217384B2 (en) Multilumen catheters and methods for their use
AU2009217383B2 (en) Multilumen catheters and methods for their use

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORAZON TECHNOLOGIES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONSTANTZ, BRENT R.;REEL/FRAME:014950/0719

Effective date: 20020423

AS Assignment

Owner name: CORDIS CORPORATION, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORAZON TECHNOLOGIES, INC.;REEL/FRAME:020609/0277

Effective date: 20060309

Owner name: CORDIS CORPORATION,FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORAZON TECHNOLOGIES, INC.;REEL/FRAME:020609/0277

Effective date: 20060309

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION